CHIR-99021 (CT99021) HCl

Catalog No.S2924

Molecular Weight(MW): 501.8

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.

Cited by 73 Publications

Nature, 2015, 10.1038/nature14413

PubMed: 25945737 ( click the link to review the publication )

Cell, 2018, 174(2):406-421

PubMed: 29887375 ( click the link to review the publication )

Nature, 2013, 500(7461):222-6

PubMed: 23812591 ( click the link to review the publication )

Cell, 2018, 174(2):391-405

PubMed: 29937225 ( click the link to review the publication )

Cell Stem Cell, 2015, 10.1016/j.stem.2015.04.020

PubMed: ( click the link to review the publication )

Circ Res, 2014, 115(6):556-66

PubMed: 25015077 ( click the link to review the publication )

Nat Protoc, 2012, 8(1):162-75

PubMed: 23257984 ( click the link to review the publication )

Nat Commun, 2015, 6:7413

PubMed: 26172574 ( click the link to review the publication )

Nat Commun, 2013, 4:2628

PubMed: 24165455 ( click the link to review the publication )

Dev Cell, 2015, 32(6):667-77

PubMed: 25805134 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(12):4484-9

PubMed: 24623855 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(52):E5039-48

PubMed: 24248365 ( click the link to review the publication )
Proc Natl Acad Sci USA, 2012, 109(27):E1848-57

PubMed: 22645348 ( click the link to review the publication )

Biomaterials, 2014, 35(5):1367-77

PubMed: 24268663 ( click the link to review the publication )

Stem Cell Res, 2015, 10.1016/j.scr.2015.05.004

PubMed: ( click the link to review the publication )

Stem Cell Rep, 2014, 3(4):594-605

PubMed: 25358788 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(5):804-16

PubMed: 25418725 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(5):804-16

PubMed: 25418725 ( click the link to review the publication )

Stem Cell Res, 2013, 12(2):364-375

PubMed: 24365601 ( click the link to review the publication )

Stem Cell Rep, 2013, 1(4):360-10

PubMed: 24319670 ( click the link to review the publication )

Antioxid Redox Sign, 2013, 20(18):2907-22

PubMed: 24219064 ( click the link to review the publication )

Acta Biomater, 2014, 10(2):604-12

PubMed: 24200714 ( click the link to review the publication )

Protein Cell, 2014, 5(1):59-68

PubMed: 24474197 ( click the link to review the publication )

Biomater Sci, 2017, 5(8):1567-1578

PubMed: 28715029 ( click the link to review the publication )
Stem Cells, 2015, 33(3):686-98

PubMed: ( click the link to review the publication )

Stem Cells, 2012, 30(9):1863-74

PubMed: 22761013 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):812-22

PubMed: 24552772 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):454-67

PubMed: 24282277 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(4):990-1007

PubMed: 24482122 ( click the link to review the publication )

Mol Neurobiol, 2015, 10.1007/s12035-014-9084-z

PubMed: 25663198 ( click the link to review the publication )

Carcinogenesis, 2012, 33(3):529-37

PubMed: 22201186 ( click the link to review the publication )

J Thromb Haemost, 2015, 10.1111/jth.12954

PubMed: 25858425 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(8):4102-16

PubMed: 23628704 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )
J Biol Chem, 2014, 289(47):32628-38

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 10.1074/jbc.M114.580076

PubMed: 25301940 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14341-50

PubMed: 24692544 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35500-10

PubMed: 24165128 ( click the link to review the publication )

J Biol Chem, 2012, 287(2):893-904

PubMed: 22102280 ( click the link to review the publication )

Am J Cancer Res, 2014, 6(6):724-735

PubMed: ( click the link to review the publication )

Mol Pharmacol, 2014, 83(5):1020-9

PubMed: 23448715 ( click the link to review the publication )

Stem Cells Dev, 2015, 10.1089/scd.2014.0422

PubMed: 25751301 ( click the link to review the publication )

Stem Cells Dev, 2014, 23(14):1688-703

PubMed: 24641164 ( click the link to review the publication )

Stem Cells Dev, 2014, 10.1089/scd.2014.0011

PubMed: 24805295 ( click the link to review the publication )

Stem Cells Dev, 2014, 23(14):1688-703

PubMed: 24641164 ( click the link to review the publication )

Exp Cell Res, 2014, 328(2):351-60

PubMed: 25172557 ( click the link to review the publication )
Cell Transplant, 2015, 10.3727/096368914X685762

PubMed: 25562386 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0161508

PubMed: 27560518 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115854

PubMed: 25541965 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85089

PubMed: 24465482 ( click the link to review the publication )

PLoS One, 2014, 9(4):e92304

PubMed: 24743237 ( click the link to review the publication )

PLoS One, 2012, 7(10):e47312

PubMed: 23077590 ( click the link to review the publication )

BMC Dev Biol, 2012, 12:21

PubMed: 22846383 ( click the link to review the publication )

Exp Biol Med, 2014, 239(10):1390-402

PubMed: 24951472 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1329-40

PubMed: 23867056 ( click the link to review the publication )

Biol Open, 2015, 4(1):48-61

PubMed: ( click the link to review the publication )

Theriogenology, 2014, 82(2):283-93

PubMed: 24853281 ( click the link to review the publication )

Cell Reprogram, 2014, 10.1089/cell.2014.0028

PubMed: 25084370 ( click the link to review the publication )
Exp Ther Med, 2016, 12(6):3851-3858

PubMed: 28101169 ( click the link to review the publication )

J Huazhong Univ Sci Technolog Med Sci, 2014, 34(2):151-6

PubMed: 24710923 ( click the link to review the publication )

Methods Mol Biol, 2016, 1353:181-90

PubMed: 25523811 ( click the link to review the publication )

Methods Mol Biol, 2016, 1480:153-65

PubMed: 27659983 ( click the link to review the publication )

J Physiol, 2015, 593(5):1147-57

PubMed: ( click the link to review the publication )

Sci Rep, 2015, 5:9718

PubMed: 25864432 ( click the link to review the publication )

Methods Mol Biol, 2015, 10.1007/7651_2015_220

PubMed: 25762297 ( click the link to review the publication )

Methods Mol Biol, 2015, 1264:453-63

PubMed: 25631034 ( click the link to review the publication )

Cell Biology International Reports, 2015, 10.1002/cbi3.10019

PubMed: ( click the link to review the publication )

University of GOTHENBURG, 2014, 5495

PubMed: ( click the link to review the publication )

Sci Rep, 2014, 4:6425

PubMed: 25236849 ( click the link to review the publication )

Methods Mol Biol, 2014, 10.1007/7651_2014_172

PubMed: 25520292 ( click the link to review the publication )
Bachelor of Science, 2012, East China Normal University

PubMed: ( click the link to review the publication )

9 Customer Reviews

Differentiation induced by treatment with the Gsk3 inhibitor in hPSCs is β-catenin dependent. H9-7TGP cells were treated with 12 uM CH in mTeSR1 for 4 d. Immunofluorescent staining for Oct4, Isl1, and Nkx2.5 was compared with GFP expression. (Scale bars, 50 uM.)

Proc Natl Acad Sci U S A 2012 109(27):E1848-57. CHIR-99021 (CT99021) HCl purchased from Selleck.

Gpc4 regulates ESC response to Wnt/β-catenin signaling. (E) Quantitative analysis of control and Gpc4-mutant beating foci exposed to the GSK3 inhibitor, CHIR 99021 (1 and 3 μM, from day 0 to day 5). Analysis was done at different time points. Gpc4- mutant cells treated with CHIR 99021 behave as controls (mean±SEM; n=2).

Stem Cells 2012 30, 1863-1874. CHIR-99021 (CT99021) HCl purchased from Selleck.
Characterization of rES cells. A: image of normal rES cell colonies on feeder layers. B: rES colonies were positive for AP staining. CeE: rES colonies readily expressed pluripotent markers, Sox2 (C), Oct4 (D), and SSEA-1 (E). Blue, DAPI. Scale bars: 100 um.

J Genet Genomics 2012 39, 643e651. CHIR-99021 (CT99021) HCl purchased from Selleck.

Inhibition of GSK3 activity induces an autophagic response in human pancreatic cancer cells. PANC1 cells were treated for 24 h with DMSO, CHIR99021 (CHIR; 5 uM) or the mTOR inhibitor Torin1 (250 nM). Autophagosome (punctate LC3B) (D) and lysosome (E) labeling was visualized with a Zeiss LSM700 confocal microscope. Images were acquired with a 20x (D) or 63x (E) objective. Nuclei were stained with DAPI. Scale bars, 20 祄.

J Biol Chem 2015 290(9), 5592-605 . CHIR-99021 (CT99021) HCl purchased from Selleck.
A. Vero cells were pretreated with the indicated concentrations of CHIR-99021 for 1 h and then infected with PEDV (MOI = 1) for 8 or 10 h. Cell lysates were prepared and analyzed using Western blotting.

PLoS One, 2016, 11(8):e0161508. CHIR-99021 (CT99021) HCl purchased from Selleck.

Smad linker phosphorylation involves GSK3 in human melanoma lines. Inhibition of Smad2 and Smad3 linker phosphorylation in the presence of the specific GSK3 specific inhibitor, CT99021. 24 hours post seeding, WM793 and 1205LU cells were serum-starved for about 16 hours, and incubated in the absence (2) or presence (+) of 2 uM of CT99021 for two hours. Immunoblots were performed as in A. p: Phosphorylated. S: Serine; T: Threonine.

PLoS One 2012 7, e47312. CHIR-99021 (CT99021) HCl purchased from Selleck.
SKOV3/DDP cells were treated with a range of concentration of (A) CHIR-99021 or in combination with 20 µM cisplatin for 48 h.

Exp Ther Med, 2016, 12(6):3851-3858. CHIR-99021 (CT99021) HCl purchased from Selleck.

PANC1 cells were treated with GSK3 inhibitors SB216763 (SB 10µM or SB 20µM) or CHIR99021 (CHIR 5µM) for 72h.

CHIR-99021 (CT99021) HCl purchased from Selleck.
Activity of canonical WNT/ β -CATENIN signals induced by CHIR 99021 in the developing human lung. Human lung tissue explants obtained at 15 weeks of gestation were exposed to 0, 5 and 10 μM CHIR 99021 in vitro for 72 h. (A-B) Western blot analysis showed expression of β -CATENIN in human lung tissues. Results are presented as the mean ± sem of three independent experiments. *P < 0.05, **P < 0.01. (C) qRT-PCR analysis detected a dose-dependent increase in WNT signaling transcription factors and target genes following exposure to CHIR 99021. Results are presented as the mean ± sem of three independent experiments. *P < 0.05, **P < 0.01. (D-K) Histology examination showed obvious morphogenetic changes of the airway epithelial cells associated with CHIR 99021 treated lung tubes. Scale bars: D-G =100 μm; H-K = 20 μm.

CHIR-99021 (CT99021) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Description

Targets

GSK-3β ^[1] (Cell-free assay)	GSK-3α ^[1] (Cell-free assay)
6.7 nM	10 nM

In vitro

CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases. Furthermore, CHIR-99021 shows only weak binding to a panel of 22 pharmacologically relevant receptors and little inhibitory activity against a panel of 23 nonkinase enzymes. CHIR-99021 induces the activation of glycogen synthase (GS) in insulin receptor-expressing CHO-IR cells with EC50 of 0.763 μM. ^[1] In addition to simulating the actions of insulin, inhibition of GSK-3 by CHIR-99021 (3 μM) increases free cytosolic β-catenin by 1.9-fold, mimicking the canonical Wnt signaling pathway in 3T3-L1 preadipocytes. During any of the first 3 days of differentiation, CHIR-99021 treatment inhibits the preadipocyte differentiation with IC50 of 0.3 μM by blocking induction of CCAAT/enhancer-binding protein α (C/EBPα) and peroxisome proliferator-activated receptor γ (PPARγ). ^[2] Unlike lithium chloride and AR-A014418, CHIR-99021 treatment does not reduce the viability of INS-1E cells even at high concentrations. Instead, CHIR-99021 robustly increases the rate of proliferation of INS-1E cells in a dose-dependent manner, and significantly inhibits INS-E cell death induced by high glucose and high palmitate in a concentration-dependent manner. CHIR-99021 promotes primary beta cell replication in isolated rat islets at concentrations as low as 1 μM, with 2-3 fold increase of cell replication at 5 μM of CHIR-99021 treatment. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
3T3-L1	NEj1eZlHfW6ldHnvckBCe3OjeR?=	NGTrSnc{KM7:TR?=	NHjjSXQ1KGh?	NHnlSGZFVVOR	NIXGWVRKdmirYnn0d{BxemWjZHnwc4N6fGViZHnm[oVz\W62aXH0bY9v	NF75XIMyOjB3NUKwNC=>
insulin receptor–expressing CHO-IR	M1vUOmZ2dmO2aX;uJGF{e2G7	M3O5TFUxOCCwTR?=	NXLqSHJnOzBibXnu	M3TxWGROW09?	MXHBZ5RqfmG2ZYOgS4x6[2:pZX6gV5lvfGijc3WgLGdUMQ>?	M1vHXVEzPjB4NEm3
H4IIE	M2HT[WZ2dmO2aX;uJGF{e2G7	MonUNVAh\|ryP	NWDNdYJxOjRiaB?=	MmjFSG1UVw>?	NHTVfI1T\We3bHH0[ZMh\|rJvY3H0[Y5qdiCjY4Tpeol1gSCjbnSgWGlTTSClb370ZYlvcW6pIIDyc41wfGW{IHHjeIl3cXS7	NUjKd4J{OTV\|NUCxPVU>
Oct4/Sox2/Klf4-infected MEFs	MXPGeY5kfGmxbjDBd5NigQ>?	MonFNVAh\|ryP	NX\jfWg{OjhiZB?=	MXnEUXNQ	MkXWVJJwdW:2ZYOgUWVHeyC{ZYDyc4dz[W2vaX7nJHRz[W6\|ZIXj[YQh[nliT3P0OEwhW2:6MjygZY5lKEuuZkS=	MXyxPVg{QTB3NR?=
Sca-1+ HPC	M2XaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LhNVIh\|ryP	MnvMOkBl	M2rGb2ROW09?	M122TnN6dmW{Z3nzeIlk[WyueTDwdo9ud3SnczDTZ4EuOSwEoFjQR{Bxem:uaX\ldoF1cW:wIHHu[EBkd2yxbomg[o9zdWG2aX;uJJRw\2W2aHXyJJdqfGhiRVfG	Mn:xNlE3OjR\|NEi=
HMC1.2	Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUe3UngxOzBizszN	MYC3NkBp	MYLEUXNQ	M4f0fHJm\HWlZYOgZ4VtdCC\|dYL2bZZidA>?	MoiyNlIxOzl\|MEG=
Endothelial cell(EC)	NHTXcHJHfW6ldHnvckBCe3OjeR?=	NXfLU5NLOyEQvF2=		NGj3S2RFVVOR	MVfQdo9ud3SnczDlcoRwfGinbHnhcEBk\WyuIDjFR{kh\GmoZnXy[Y51cWG2aX;u	NXPTfIRTOjJyNUKwNFY>
PANC1	MYLBdI9xfG:\|aYOgRZN{[Xl?	NYHvUYZWyqB3IN88US=>	MXy3NkBp	MmjCSG1UVw>?	NIfYNZBVemmpZ3Xyd{BidiCjcH;weI91cWNicnXzdI9ve2V?	NWLTe\|Z7OjJ{MEGxPFY>
INS-1E	MUPGeY5kfGmxbjDBd5NigQ>?	NFHCNIIzNjVizszN	MljxNlQhcA>?	M171XWROW09?	MoLiTY5lfWOnczDhJJJm\HWldHnvckBw\iCQUEGgc5ZmemW6cILld5Nqd25?	Mlv1NlI1Ojd5MES=
hiPSC-NPs	NV6yTYVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPaU2NjO+LCid88US=>	M17XXFczKGh?	MnTVSG1UVw>?	MmXTTY5kemWjc3XzJINmdGxicILvcIln\XKjdHnvcuKh	M1nFOlIzPjR{Nki3
platelets	NFS5d3dHfW6ldHnvckBCe3OjeR?=	MYWxNEDPxE1?	MnPvNVUhdWmw	M2DBb2ROW09?	M1rYd2lv[3KnYYPld{B1cHKxbXLpck1u\WSrYYTl[EBxdGG2ZXzleEBi\2e{ZXfheIlwdiCjbnSgRXRRKHOnY4LleIlwdg>?	Mo\mNlMzOzl6N{e=
DN3	NWP6XJVETnWwY4Tpc44hSXO\|YYm=	NFnpOmUyOCEQvF2=	NWG4XpBDQTZiaB?=	M3HVemROW09?	NUPTV2xoUW6lcnXhd4V{KGOnbHyg[IV3\WyxcH3lcpQh[W6mIIDyc4xq\mW{YYTpc44>	M365XFI{PTJ4OUi5
embryonic stem cells (ESC)	NWjmTWJHTnWwY4Tpc44hSXO\|YYm=	MVKzJOK2VQ>?	NVHGdoVUOTFiZB?=	NID2WnFFVVOR	MnW2VJJwdW:2ZYOgd4Vt\i2{ZX7le4FtKG:oIH7hx893\S22eYDlJI1wfXOnIHXtZpJ6d26rYzDzeIVuKGOnbHzzJEhGW0Nr	MnH3NlM5PDN\|MUK=
H460	NFG1XJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYG1JOK2VQ>?	M{m1SVI1KGh?	NETlWGVFVVOR	NXj3dFhjWHKxbX;0[ZMh[2WubDDwdo9tcW[ncnH0bY9v	NWjCXndSOjR\|Nke2PFg>
H157	M2TN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LvflUhyrWP	MVKyOEBp	MY\EUXNQ	Mkj0VJJwdW:2ZYOgZ4VtdCCycn;sbYZmemG2aX;u	MYmyOFM3PzZ6OB?=
H460	MVvBdI9xfG:\|aYOgRZN{[Xl?	MV61JOK2VQ>?	NEHLXGYzPCCq	M4HmV2ROW09?	NUnuepNzSXS2ZX71ZZRmeyClZXzsJIFxd3C2b4Ppdy=>	M{X3TFI1OzZ5Nki4
H157	MkWyRZBweHSxc3nzJGF{e2G7	Ml\EOUDDvU1?	NUjYblFbOjRiaB?=	NUjS[5NuTE2VTx?=	M{H2TmRw\XNibn;0JJNq\26rZnnjZY51dHliYX\m[YN1KGGyb4D0c5Nqew>?	NWrSU2JWOjR\|Nke2PFg>
A549	M4DyS2Fxd3C2b4Ppd{BCe3OjeR?=	NVzpS3hxPSEEtV2=	M3TGfVI1KGh?	NWj2TY9DTE2VTx?=	NXTKS2dKUW6lcnXhd4V{KGOnbHygZZBweHSxc3nz	M4[zW\|I1OzZ5Nki4
Neural progenitor cells	MXfGeY5kfGmxbjDBd5NigQ>?	NX\1U4xiOyEQvF2=	NF:5UmYyOCCm	NUTLVZp1TE2VTx?=	NFWwToRKdmS3Y3XzJIdmdmW{YYTpc44hd2ZibnX1doFtKHC{b3flcol1d3JiY3XscJM>	NUXBTHRrOjR4M{iwN\|Q>
ES-D3	NFzTXY5EgXSxdH;4bYMhSXO\|YYm=	M4fjfFExyqEQvF2=	NVHQb5ZEOyCm	NFLF[\|JFVVOR	M4TnZmlv\HWlZYOgcY9l\XKjdHWgZ5l1d3SxeHnjbZR6KHerdHigTWM2OCCxZjC0Mlkh\|ryP	NHHVNYMzPDd5OUO2OS=>
ES-CCE	NWLxb\|dMS3m2b4TvfIlkKEG\|c3H5	M3TzV\|ExyqEQvF2=	MXWzJIQ>	M4TOfWROW09?	MnTjTY5lfWOnczDtc4RmemG2ZTDjfZRwfG:6aXPpeJk>	NX;0bW4yOjR5N{mzOlU>
ES-D3	MVzGeY5kfGmxbjDBd5NigQ>?	M4PuWlXDqM7:TR?=	NWnvWphxOyCm	MXHEUXNQ	NH;lNotUfHKxbnfsfUBqdmS3Y3XzJJRp\SCjY4Tpeol1gSCxZjDXcpQw[mW2YT3jZZRmdmmwIIDheIh4[Xl?	MYGyOFc4QTN4NR?=
ES-CCE	M2j0U2Z2dmO2aX;uJGF{e2G7	NYPOOIdoPcLizszN	MXqzJIQ>	Ml7RSG1UVw>?	NVnh[IdyW3S{b37ncJkhcW6mdXPld{B1cGViYXP0bZZqfHlib3[gW451N2KndHGtZ4F1\W6rbjDwZZRpf2G7	Mki0NlQ4Pzl\|NkW=
SW982	NYrpRWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2G4OWlEPTB;MD6yNVQyPiEQvF2=	MYnTRW5ITVJ?
GCT	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LFPGlEPTB;MD6zNFY4OiEQvF2=	NIOwfZpUSU6JRWK=
769-P	NW\KT\|dvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDVVmw2UUN3ME2wMlU5PDl7IN88US=>	M4PTenNCVkeHUh?=
LOXIMVI	Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\wS5dKSzVyPUCuOVg5OzJizszN	M{\JRXNCVkeHUh?=
D-336MG	M1vZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\PTWM2OD1yLki0OlIh\|ryP	NH;KW2xUSU6JRWK=
S-117	MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mof6TWM2OD1yLkmyNVMyKM7:TR?=	NIraT25USU6JRWK=
D-247MG	M1vmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVv0U\|Q4UUN3ME2wMlk1QDV{IN88US=>	MmLGV2FPT0WU
TYK-nu	NGf3emJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HaNWlEPTB;MT6wO\|kyOiEQvF2=	NWXIXY85W0GQR1XS
A498	NVT0fldpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3kPWRKSzVyPUGuN\|A1PjlizszN	MnzMV2FPT0WU
BCPAP	NE\jPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rsVmlEPTB;MT62Olg6QCEQvF2=	MYfTRW5ITVJ?
KYSE-180	M2jJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHWZXFKSzVyPUGuO\|I4QDhizszN	NXvVXlM3W0GQR1XS
MIA-PaCa-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTFwN{W5O\|ch\|ryP	NUDM[JF1W0GQR1XS
HCC1395	M4mwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTFwN{iyO\|Mh\|ryP	NEi4TZlUSU6JRWK=
RS4-11	NXzPTolTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDqTmc4UUN3ME2xMlk2PDF3IN88US=>	Ml3mV2FPT0WU
NCI-H2122	NHTmZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFuzOohKSzVyPUKuNlc3QDRizszN	MXfTRW5ITVJ?
SNU-423	M{\XRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmf2TWM2OD1{LkS5O\|g4KM7:TR?=	NXPIWGZTW0GQR1XS
SK-LMS-1	NX3aeFVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHLSpdKSzVyPUKuOlQyOjhizszN	M4PMO3NCVkeHUh?=
RPMI-7951	NWHKVGpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPCeJNuUUN3ME2yMlcxOTl\|IN88US=>	NG\LN4hUSU6JRWK=
COLO-829	Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXYUFNMUUN3ME2yMlc3PTRizszN	M{nSe3NCVkeHUh?=
SCC-9	NFHQZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTJwOUW0PFUh\|ryP	MVvTRW5ITVJ?
A704	NHLxXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTRNVZIUUN3ME2zMlA5OTJizszN	NWjjUpFJW0GQR1XS
HOP-62	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjrUFFKSzVyPUOuN\|YxPTRizszN	M1;xUXNCVkeHUh?=
HCC1569	NWDMRnhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTNwNEizNFUh\|ryP	NGLveXRUSU6JRWK=
A172	NUfBZ2FuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3SOpZKUUN3ME2zMlc2PDl6IN88US=>	MX7TRW5ITVJ?
MOLT-16	NFHYU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTNwOEi1OVYh\|ryP	NGjIU4RUSU6JRWK=
TE-15	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTNwOUWzOFMh\|ryP	NFrUZYdUSU6JRWK=
OE19	M2rwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\DbYJKSzVyPUOuPVY1PTFizszN	MoHCV2FPT0WU
MHH-ES-1	NFKyPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF31NYJKSzVyPUSuNFQ2PDVizszN	NVXkOZpkW0GQR1XS
NKM-1	MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LkfmlEPTB;ND6xN\|k4OSEQvF2=	NVnRT3Y1W0GQR1XS
RCC10RGB	MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3n4WmlEPTB;ND6yPVQ4QSEQvF2=	MkDTV2FPT0WU
BxPC-3	M2TWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmCyTWM2OD12LkewN\|kyKM7:TR?=	NHPCUIdUSU6JRWK=
ALL-PO	NHK1O2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTjTWM2OD12LkizPFU5KM7:TR?=	NWTtRnhnW0GQR1XS
SK-OV-3	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nK[WlEPTB;ND65PVM1KM7:TR?=	M3PKZ3NCVkeHUh?=
SW1710	M2C5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTVwNEK0OVYh\|ryP	NV7kWoNQW0GQR1XS
NCI-H2452	MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLyTWM2OD13LkS1OlI5KM7:TR?=	MVPTRW5ITVJ?
D-392MG	NUnmdVdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\GTWM2OD13LkS5NVQ2KM7:TR?=	Mmj0V2FPT0WU
LB2518-MEL	M2nUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLNcWU4UUN3ME21MlczPjJ5IN88US=>	M1\US3NCVkeHUh?=
BL-41	M{LNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTVwOEGyOlYh\|ryP	MUTTRW5ITVJ?
WM-115	Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TUSmlEPTB;NT64NVUxQSEQvF2=	NWq5SZM6W0GQR1XS
SK-MEL-2	NXXqUo92T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEG3VlJKSzVyPU[uN\|g{PDRizszN	NWXwTo9HW0GQR1XS
CGTH-W-1	NGDsXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTTXnlxUUN3ME22MlQyPyEQvF2=	NXH3OIZOW0GQR1XS
BB65-RCC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\BdGlEPTB;Nj61N\|E6PSEQvF2=	Mn23V2FPT0WU
CAL-85-1	MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPkRnJSUUN3ME22MlYxQTN4IN88US=>	MXvTRW5ITVJ?
RT-112	NF3xbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTdwMU[0OVYh\|ryP	NIrOR5dUSU6JRWK=
MC116	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzaPFFKSzVyPUeuNlg3QTFizszN	Mo\aV2FPT0WU
G-361	M17QdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3joNmlEPTB;Nz60OlU3OSEQvF2=	MUHTRW5ITVJ?
SW1417	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTdwNkS1PFQh\|ryP	NFvRU3lUSU6JRWK=
MV-4-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fjVmlEPTB;OD61OFMxPCEQvF2=	MmnVV2FPT0WU
CAL-72	M1XMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\sNWlEPTB;OD63OlEyOyEQvF2=	NWPZUFB{W0GQR1XS
MKN28	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRThwOEi1NVYh\|ryP	NETPc21USU6JRWK=
MEG-01	NWPpd2NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfsR5FKSzVyPUiuPVkxPDNizszN	MXrTRW5ITVJ?
ACHN	NHnNfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M12zcmlEPTB;OT6zNFU1PiEQvF2=	MWjTRW5ITVJ?
NCI-H1755	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DnO2lEPTB;OT6zPVk5PiEQvF2=	M3LYZ3NCVkeHUh?=
NCI-H64	NITMXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXjc4tKSzVyPUmuOFIzPTVizszN	MV\TRW5ITVJ?
COLO-205	M1K3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTJXZJlUUN3ME25MlQ{QDJzIN88US=>	Mk\sV2FPT0WU
CTV-1	MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTlwNEO4PVQh\|ryP	MoLiV2FPT0WU
U-2-OS	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHniSmNKSzVyPUmuOFUxODZizszN	MlixV2FPT0WU
LB996-RCC	NFPaPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEm3ZmVKSzVyPUmuOVI{QTdizszN	NXmxe2dvW0GQR1XS
SK-N-DZ	NYTrXnVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1q2Z2lEPTB;OT62OVc1OiEQvF2=	NYXzR4o1W0GQR1XS
EFM-19	MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLwdHpKSzVyPUmuO\|U2PjZizszN	MXzTRW5ITVJ?
DBTRG-05MG	M4S2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDOXJNKSzVyPUmuO\|c4PyEQvF2=	NUXDRoNsW0GQR1XS
U-118-MG	NYTWR5dyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3P0NmlEPTB;OT65OFQ1PCEQvF2=	NU\sPHo3W0GQR1XS
LB1047-RCC	M1uxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fuWmlEPTB;OT65PVc6QCEQvF2=	MlntV2FPT0WU
NCI-H28	MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\GTWM2OD1zMD60OFE{KM7:TR?=	NGLkbXZUSU6JRWK=
MZ2-MEL	NULPdmUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn71TWM2OD1zMD60Olc4KM7:TR?=	NYTr[2NiW0GQR1XS
M059J	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LuNWlEPTB;MUCuOlExOiEQvF2=	MXvTRW5ITVJ?
HT-3	NVjVU2E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVftXZZsUUN3ME2xNE43OTd7IN88US=>	NWD4T2VUW0GQR1XS
SNU-387	NYTJcZhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTSZo1KSzVyPUGwMlczOzVizszN	NYH0XYQ1W0GQR1XS
NCI-H526	NEexWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoC3TWM2OD1zMT6xN\|Y2KM7:TR?=	M17senNCVkeHUh?=
HEL	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfyRpZrUUN3ME2xNU43PTd7IN88US=>	NFnr[G5USU6JRWK=
PA-1	NUnaU5VYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmGyTWM2OD1zMT65N{DPxE1?	M3nqUnNCVkeHUh?=
PC-14	M3XTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\QTWM2OD1zMj6zNlQh\|ryP	NHHjeZRUSU6JRWK=
C8166	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTF\|LkKzNVgh\|ryP	M37UUnNCVkeHUh?=
NCI-H82	NUPlVlVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjuTWM2OD1zMz6yPVA6KM7:TR?=	M2Tvd3NCVkeHUh?=
DSH1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmr5TWM2OD1zMz6zPFc6KM7:TR?=	M1fKcnNCVkeHUh?=
T98G	NXLsZYFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;ZTWM2OD1zMz60O\|E4KM7:TR?=	MXPTRW5ITVJ?
KU812	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTF\|LkWxO\|Uh\|ryP	MW\TRW5ITVJ?
SW48	M3;yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYT4VHpqUUN3ME2xN{44OjZ3IN88US=>	NIeyb5hUSU6JRWK=
MEL-HO	NWnJTG9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTF\|Lki4Nlkh\|ryP	NHLyfVdUSU6JRWK=
SF539	NVTrXJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2raZWlEPTB;MUSuNFEyPiEQvF2=	NVnwUVVEW0GQR1XS
NB1	NVvscGV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTF2LkG5N\|Uh\|ryP	MoTPV2FPT0WU
ST486	NFPl[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTF2LkKyOVEh\|ryP	MVnTRW5ITVJ?
LoVo	NGHROGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzITWM2OD1zNT6yOlU6KM7:TR?=	MlrTV2FPT0WU
NH-12	M{T4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfCZmRKSzVyPUG2MlAxQTdizszN	MlS3V2FPT0WU
CCRF-CEM	Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTF4Lk[3NFIh\|ryP	NVTqNYp4W0GQR1XS
Daudi	MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4q2NmlEPTB;MUeuOlE1QSEQvF2=	NYXOb41pW0GQR1XS
SIMA	NEDTephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXOOZFKSzVyPUG3MlkyOThizszN	MofvV2FPT0WU
8305C	M{DqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;BVoFKSzVyPUG4MlU{ODVizszN	Mnn4V2FPT0WU
EM-2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTvTWM2OD1zOD62NlQ5KM7:TR?=	M3v4O3NCVkeHUh?=
SNU-449	Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33sUmlEPTB;MUiuO\|E2KM7:TR?=	M2LBWHNCVkeHUh?=
A101D	MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEO1OHZKSzVyPUG5MlI1OyEQvF2=	MWjTRW5ITVJ?
MHH-NB-11	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\DXJdmUUN3ME2xPU42OzR{IN88US=>	MkTkV2FPT0WU
Becker	MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIqxc\|BKSzVyPUKwMlE4PzdizszN	NX3qT4lZW0GQR1XS
NCI-H727	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTJyLkKxOlkh\|ryP	MULTRW5ITVJ?
HCC1187	M3;rSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPNcYVKSzVyPUKwMlM2QDlizszN	Mkj4V2FPT0WU
KYSE-450	NVfsN2p7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEW1d4xKSzVyPUKxMlU{PTRizszN	MV3TRW5ITVJ?
SK-MEL-28	NFPa[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTJzLk[4OlMh\|ryP	NVnH[WhyW0GQR1XS
BPH-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTJzLkewN\|Uh\|ryP	Mk\FV2FPT0WU
EoL-1-	M{fDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHqx[2NKSzVyPUKxMlg{QDVizszN	NVnpU5JKW0GQR1XS
TGBC24TKB	NHLCO\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTJzLki5OVch\|ryP	MnnrV2FPT0WU
KARPAS-299	NWTGPYFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTJ{LkG5OVQh\|ryP	NELJRVhUSU6JRWK=
SW684	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjKZW9KSzVyPUKyMlI5PThizszN	MVXTRW5ITVJ?
RXF393	NF3XR2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DINWlEPTB;MkKuOlA3QCEQvF2=	MmrsV2FPT0WU
LS-513	NVrJfWRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTJ{Lk[xPVIh\|ryP	MoXRV2FPT0WU
KURAMOCHI	MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTJ{LkewOlkh\|ryP	NHPiPZBUSU6JRWK=
GI-1	MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3xRZJKSzVyPUKyMlc5PDFizszN	NEjOe4hUSU6JRWK=
M14	NEm3bI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33R[WlEPTB;MkOuNVE{OiEQvF2=	NHnwSnVUSU6JRWK=
REH	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzNTWM2OD1{Mz6xOlk6KM7:TR?=	NH3BdHFUSU6JRWK=
K5	NIrLfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Xm[WlEPTB;MkOuOVQ5PiEQvF2=	M2rLTnNCVkeHUh?=
PANC-10-05	M3;yZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnDOYJKSzVyPUK0MlA5QThizszN	MVLTRW5ITVJ?
HMV-II	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLa[3hKSzVyPUK0MlIyPjNizszN	NWLpNmN4W0GQR1XS
NCI-H1963	NX\KNphZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\5W4ZUUUN3ME2yOE4zQDN7IN88US=>	M3LxVnNCVkeHUh?=
LU-139	NYXJ[\|VnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXT0dZpiUUN3ME2yOE45OzVizszN	MYfTRW5ITVJ?
KASUMI-1	MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{H5[2lEPTB;MkSuPVMzQCEQvF2=	M2DJWnNCVkeHUh?=
RO82-W-1	NYTtTplWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojtTWM2OD1{Nj63N\|c4KM7:TR?=	M3XJSHNCVkeHUh?=
NCI-H1770	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTJ4Lki5PFYh\|ryP	MknQV2FPT0WU
SNG-M	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HUWmlEPTB;MkeuNlI4OSEQvF2=	NYrJbohwW0GQR1XS
KLE	NF7hN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFr5VJlKSzVyPUK3MlI2PjVizszN	MXfTRW5ITVJ?
NCI-H2170	NIjUXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3qbHRrUUN3ME2yO{42Ojh{IN88US=>	NXjLSo5NW0GQR1XS
COLO-792	NX;TfpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjkbVBJUUN3ME2yO{44PzJ6IN88US=>	MmW0V2FPT0WU
ES8	MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LKTmlEPTB;MkeuO\|gyPCEQvF2=	NUi5PXN3W0GQR1XS
MC-CAR	MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWC5N2FrUUN3ME2yO{44QTB5IN88US=>	NX;o[YFoW0GQR1XS
SU-DHL-1	NFy1dYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTDTWM2OD1{Nz65OFc1KM7:TR?=	MVPTRW5ITVJ?
OAW-28	Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTJ6LkCwOVIh\|ryP	NEXQe2NUSU6JRWK=
C32	NX\VeHV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3i4TmlEPTB;MkiuNFgzPiEQvF2=	MWjTRW5ITVJ?
SW872	NHviOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{L6fGlEPTB;MkiuOVMzPiEQvF2=	MWDTRW5ITVJ?
JiyoyeP-2003	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTJ7Lk[3NVkh\|ryP	Ml3lV2FPT0WU
A204	NVv0[IxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmf4TWM2OD1{OT62PFI5KM7:TR?=	MmnVV2FPT0WU
IST-MES1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3DU3JKSzVyPUK5MlcxQTJizszN	M4HWZ3NCVkeHUh?=
LCLC-103H	M33Q[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTEdHZkUUN3ME2zNE4zODV7IN88US=>	NVW0WpFjW0GQR1XS
CAKI-1	NGLjUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorKTWM2OD1\|MD6yOlU3KM7:TR?=	NELidYhUSU6JRWK=
NALM-6	NXjrV3lYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXkXHlKSzVyPUOwMlQ6PjVizszN	MoPYV2FPT0WU
SK-MM-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1P6dWlEPTB;M{CuPVc6OiEQvF2=	NGfiRmxUSU6JRWK=
LB373-MEL-D	MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIC2O\|RKSzVyPUOxMlAxPDdizszN	NEjkR2dUSU6JRWK=
CAS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XUXmlEPTB;M{GuO\|Y3PSEQvF2=	MWTTRW5ITVJ?
KNS-42	M1rw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTNzLki2OlIh\|ryP	NHPZe\|JUSU6JRWK=
SW948	M1rZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzrTWM2OD1\|Mj63OVQ5KM7:TR?=	NYH3S\|FnW0GQR1XS
HCC1143	NX3pV2d6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnuUVVPUUN3ME2zNk44QTd7IN88US=>	NXm4fZNrW0GQR1XS
NCI-H1648	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEe4WFdKSzVyPUOyMlg1PjdizszN	M1j2SnNCVkeHUh?=
RVH-421	MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvqTWM2OD1\|Mz6xOlgh\|ryP	NVLuflgzW0GQR1XS
KU-19-19	NWS5O5c6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTN\|Lke1N\|Qh\|ryP	M1rsNHNCVkeHUh?=
PFSK-1	NWnDSHJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnsTWM2OD1\|ND65NlQyKM7:TR?=	M1flbHNCVkeHUh?=
TK10	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2ftT2lEPTB;M{WuNVMzOiEQvF2=	NWP1[\|dqW0GQR1XS
IGROV-1	NF\SW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;KXod5UUN3ME2zOU4{PDF4IN88US=>	MXvTRW5ITVJ?
EFE-184	M4La[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TuemlEPTB;M{WuPVE4KM7:TR?=	NUHNW4w1W0GQR1XS
8505C	NGf6NlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTN3LkmyPVQh\|ryP	MlLxV2FPT0WU
SK-UT-1	MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXUTWM2OD1\|Nj6zN\|MyKM7:TR?=	NXz1Z2FkW0GQR1XS
MKN1	MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfyXWRKSzVyPUO2Mlg1PDRizszN	NV7JUHRRW0GQR1XS
no-10	MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XM[WlEPTB;M{iuNVI6PCEQvF2=	M3HsUnNCVkeHUh?=
HT-144	NYLTdllyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfJcok{UUN3ME2zPE4zPTd3IN88US=>	M1TsV3NCVkeHUh?=
CMK	M1rnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTEfZZKSzVyPUO4MlQyPjJizszN	NYq4SpYyW0GQR1XS
KM12	NGGxZ\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlv5TWM2OD1\|OD61PVk5KM7:TR?=	NFjzRmRUSU6JRWK=
HCC2218	NF2zNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTRyLkW4OFkh\|ryP	NVnPU4FFW0GQR1XS
BE-13	M4\ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{niUWlEPTB;NEGuOFQ4OyEQvF2=	NXXydXhwW0GQR1XS
SK-CO-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NECwTIJKSzVyPUSxMlc4PTVizszN	MkLyV2FPT0WU
MPP-89	Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTRzLkmyNVEh\|ryP	MYnTRW5ITVJ?
NY	M3\2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTR{LkG4NFEh\|ryP	NF;5e25USU6JRWK=
IST-MEL1	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPHcmhKSzVyPUSyMlY6OzhizszN	MnXaV2FPT0WU
HCT-116	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYj1N\|V5UUN3ME20N{4zODl7IN88US=>	MkDIV2FPT0WU
LB831-BLC	NV72UFZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTR\|Lk[5O{DPxE1?	M3K3cnNCVkeHUh?=
TE-8	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\yOndKSzVyPUSzMlc5QTVizszN	NUPndnluW0GQR1XS
SR	NHOwZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoP4TWM2OD12Mz64Olc{KM7:TR?=	NHXXXY9USU6JRWK=
ESS-1	M1HqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLoNXdKSzVyPUS0MlIxPjJizszN	MY\TRW5ITVJ?
KYSE-270	M2LkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTR3LkC0N\|ch\|ryP	Ml7sV2FPT0WU
H4	MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\qd4NXUUN3ME20OU4{Ojl4IN88US=>	M3fkTHNCVkeHUh?=
COLO-800	M2Cx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTR3LkW4PVgh\|ryP	M{PiVXNCVkeHUh?=
Ramos-2G6-4C10	NH[weplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3y3[mlEPTB;NE[uNFc2PSEQvF2=	NXzkOG97W0GQR1XS
no-11	M{Ljd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;6U3RXUUN3ME20Ok4zODNzIN88US=>	NX[yXnEyW0GQR1XS
UACC-62	NHi4XZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\Ieo9KSzVyPUS2Mlg3ODhizszN	MYnTRW5ITVJ?
D-542MG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUG5eWhlUUN3ME20O{41PTh7IN88US=>	M1LEeXNCVkeHUh?=
NCI-H747	NFnnTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULGTZVSUUN3ME20O{44OjZ2IN88US=>	MYLTRW5ITVJ?
HCC2998	NXH3XW5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4K0cWlEPTB;NEiuNlk5OiEQvF2=	M2TLe3NCVkeHUh?=
SNB75	M3LyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfk[WFKSzVyPUS4MlQyOThizszN	MVjTRW5ITVJ?
COR-L105	M3\n[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvpeYVOUUN3ME20PE46PzNizszN	MV3TRW5ITVJ?
SNU-C1	MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfoTWM2OD12OT6zNlA4KM7:TR?=	NXm3OIZkW0GQR1XS
LC4-1	NYPGWJM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX[5XVY3UUN3ME20PU45QTF{IN88US=>	NGfvd\|VUSU6JRWK=
KS-1	M{PQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjieVhWUUN3ME21NE4zOjJ3IN88US=>	NVzndpp[W0GQR1XS
NCI-H1793	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoD3TWM2OD13MT6yN\|Eh\|ryP	M4nDO3NCVkeHUh?=
NCI-H1650	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTVzLkW4OFkh\|ryP	MVrTRW5ITVJ?
MCF7	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfVbos4UUN3ME21NU44PTV2IN88US=>	NYjEfnJyW0GQR1XS
SK-N-AS	NWPZfFh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFewcm5KSzVyPUWxMlgzQDFizszN	MlnXV2FPT0WU
SW837	NWD6XZM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPDTWM2OD13MT65O\|g2KM7:TR?=	M4T0PXNCVkeHUh?=
DB	NF6zV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfVTWM2OD13MT65PFU2KM7:TR?=	NGPoZVdUSU6JRWK=
CESS	MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTV{LkG0OUDPxE1?	MYXTRW5ITVJ?
CHP-126	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTV\|LkWxOlkh\|ryP	MYnTRW5ITVJ?
COLO-824	M4PVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXIfnBKSzVyPUWzMlY6PzZizszN	MmDuV2FPT0WU
MG-63	NXLYbGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7VTWM2OD13Mz65N\|gyKM7:TR?=	NIfqXldUSU6JRWK=
KGN	M2jXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLESFAzUUN3ME21N{46PTlizszN	MnzMV2FPT0WU
697	NVL6d4h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1r3PWlEPTB;NUSuNVU2PSEQvF2=	NWLWNXRpW0GQR1XS
MC-IXC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHYTWM2OD13ND60N\|Y1KM7:TR?=	NWPsPZRTW0GQR1XS
A375	NWi3OW14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Sy[2lEPTB;NUSuPFA2QSEQvF2=	MULTRW5ITVJ?
LXF-289	M{XKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7pNo5QUUN3ME21OU42ODZ4IN88US=>	NX;pOWNkW0GQR1XS
ES6	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17hNmlEPTB;NUWuPFg6QSEQvF2=	NGjLNXdUSU6JRWK=
DV-90	MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTV3Lki5NVch\|ryP	NETnfJdUSU6JRWK=
RCM-1	M4Gz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TYTGlEPTB;NU[uNFA4QCEQvF2=	NWOyO3V5W0GQR1XS
NCI-H2405	NWPOSHN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;NV3JiUUN3ME21Ok4yPjl\|IN88US=>	MnLqV2FPT0WU
DoTc2-4510	M{S0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmr4TWM2OD13Nj62NFU4KM7:TR?=	MYXTRW5ITVJ?
RPMI-8866	NIDwd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnlOplKSzVyPUW3MlI1OTJizszN	NHO2cXZUSU6JRWK=
BV-173	MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fET2lEPTB;NUeuOVE1OiEQvF2=	NXy2e4xPW0GQR1XS
LCLC-97TM1	NGLvO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\xfWlEPTB;NUmuNFU2OyEQvF2=	M4PJfnNCVkeHUh?=
HT-1376	M3LvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\lUndKSzVyPUW5MlA6OjFizszN	NHzjXZhUSU6JRWK=
ACN	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTV7LkG1PFch\|ryP	MojCV2FPT0WU
LU-134-A	M3;VeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\EcGlEPTB;NUmuOlAyPiEQvF2=	NVjPT\|g1W0GQR1XS
SiHa	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjLe41zUUN3ME21PU43PDh5IN88US=>	M4LlbHNCVkeHUh?=
EKVX	NVr0OW5HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfNU4U3UUN3ME22NU41QTV6IN88US=>	MlzvV2FPT0WU
NMC-G1	NIjxN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXrTWM2OD14MT65NlQzKM7:TR?=	M{LUV3NCVkeHUh?=
NCI-H1734	M37vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXlb4p1UUN3ME22NU46PjZ\|IN88US=>	M{nUW3NCVkeHUh?=
K-562	M4XVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTZ{LkK0OVIh\|ryP	MX7TRW5ITVJ?
T-24	M13me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX74Oo5sUUN3ME22Nk44OTJ4IN88US=>	NHPOcm1USU6JRWK=
SCH	NW\ufIpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDHbXRbUUN3ME22OE4zOzVzIN88US=>	NUXDbWhUW0GQR1XS
AN3-CA	M3u4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHSOFFKSzVyPU[0MlMxOzVizszN	MX3TRW5ITVJ?
MFE-296	NGC5elBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zTdWlEPTB;NkSuOFQ4OyEQvF2=	Mly2V2FPT0WU
HuCCT1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTZ5LkCzO\|Qh\|ryP	MWfTRW5ITVJ?
NCI-H1703	NG\DZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3H5[WlEPTB;NkiuNVE4OSEQvF2=	M{e4fHNCVkeHUh?=
C-4-II	M2HISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DSPGlEPTB;NkmuN\|YxPyEQvF2=	MWrTRW5ITVJ?
NCI-H2342	NWD0NYdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTZ7LkO5OlEh\|ryP	MUfTRW5ITVJ?
Hs-578-T	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTdyLkOg{txO	NWfofmt2W0GQR1XS
HCC1806	M3\rS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnmTWM2OD15MT60OVg4KM7:TR?=	M4[yd3NCVkeHUh?=
EW-16	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHS5VFdKSzVyPUexMlc1OTVizszN	MnzwV2FPT0WU
KALS-1	M1vBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MniwTWM2OD15Mz61OFc2KM7:TR?=	MmrSV2FPT0WU
RT4	NXXFTnpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjsVoNKSzVyPUezMlU4PDJizszN	MUHTRW5ITVJ?
LS-411N	M3H6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TGNmlEPTB;N{SuNlUzQCEQvF2=	NVvQd2NnW0GQR1XS
SK-MEL-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWe3V4ZHUUN3ME23OU45ODF7IN88US=>	NIX6WFJUSU6JRWK=
8-MG-BA	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTjTWM2OD15Nj6xNFk3KM7:TR?=	MlrDV2FPT0WU
HSC-3	M1rCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLDc\|drUUN3ME23O{4xOjh{IN88US=>	MlnlV2FPT0WU
NB6	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\PTWM2OD15OD6xNlk6KM7:TR?=	M1HuOHNCVkeHUh?=
PANC-03-27	NGXPSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fjcmlEPTB;N{iuOFM2KM7:TR?=	NYL1S2FzW0GQR1XS
KP-N-YS	NFfKTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIS0bJJKSzVyPUe4MlU5PzhizszN	MknqV2FPT0WU
SF295	MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDQTWM2OD15OT65OVU{KM7:TR?=	NVXEXVh4W0GQR1XS
HCE-T	NEm0copIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnocmNKSzVyPUiwMlE2QDhizszN	MWfTRW5ITVJ?
KYSE-410	MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRThyLkK4OVch\|ryP	M3\Mc3NCVkeHUh?=
NB12	NUDpUoV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRThyLkmzOlkh\|ryP	NV;qOld6W0GQR1XS
NCI-H661	NUHlc5VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPxVVFKSzVyPUixMlM1PCEQvF2=	NWjN[5hwW0GQR1XS
NCI-H1417	NWHK[XRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHewb4NKSzVyPUixMlQ{PjhizszN	MYDTRW5ITVJ?
KMOE-2	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorQTWM2OD16MT64OVMyKM7:TR?=	NFn1ZpZUSU6JRWK=
SW1573	NFu5UWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTh{LkW4PVMh\|ryP	NWPGS5JKW0GQR1XS
BFTC-905	M163VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnTe5lNUUN3ME24OE4xOTd{IN88US=>	MljCV2FPT0WU
SBC-1	NEC2bFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHVTWM2OD16ND6wNlA5KM7:TR?=	MYfTRW5ITVJ?
MDA-MB-175-VII	NFjLdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjLUJVKSzVyPUi1Mlc1OjZizszN	MnjPV2FPT0WU
TE-12	NYOyRWxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXrTWM2OD16OT6zO\|QyKM7:TR?=	NULZWXBFW0GQR1XS
NCI-H650	M2rUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH61cZlKSzVyPUi5Mlg4OjRizszN	Ml7mV2FPT0WU
C-33-A	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorqTWM2OD17MD61OEDPxE1?	NX7Id5ZtW0GQR1XS
MZ7-mel	NFXlcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jrSGlEPTB;OUGuNlY4PiEQvF2=	MnW5V2FPT0WU
BOKU	Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDkTWM2OD17Mj62PVU4KM7:TR?=	MULTRW5ITVJ?
CAL-33	NWjSSYd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUG0RlY2UUN3ME25N{4xPjBzIN88US=>	NIrCNnJUSU6JRWK=
23132-87	NH3pUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnENmh4UUN3ME25N{4yPjhizszN	NXnDWlZjW0GQR1XS
J82	NWDiTIFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7YeHhKSzVyPUmzMlc5OTFizszN	MkPxV2FPT0WU
MZ1-PC	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTl2LkW5PFQh\|ryP	NGjlSYpUSU6JRWK=
MEL-JUSO	NGTl[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlz5TWM2OD17ND65OVQh\|ryP	NWHCOGtJW0GQR1XS
RMG-I	M4H6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkf1TWM2OD17NT6xNFczKM7:TR?=	MX\TRW5ITVJ?
A2058	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\aNGlEPTB;OUWuOFYyPyEQvF2=	MYDTRW5ITVJ?
Caov-4	NXvnU\|FoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlH5TWM2OD17NT62PFUh\|ryP	MmTOV2FPT0WU
OS-RC-2	M1\MTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3KyfGlEPTB;OUeuOFYyKM7:TR?=	MVvTRW5ITVJ?
MKN7	NH7Od3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\VPHpxUUN3ME25O{44PDN7IN88US=>	NEfMcY5USU6JRWK=
U-698-M	M2fDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XidWlEPTB;OUiuPVQ5QSEQvF2=	MYfTRW5ITVJ?
PC-3	NXnXXml4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTl7LkC1OlQh\|ryP	NIHKbJFUSU6JRWK=
NCI-H292	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrMZ2pKSzVyPUm5MlMxODRizszN	NYHHeZRVW0GQR1XS
IGR-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2i2RmlEPTB;OUmuN\|EyQSEQvF2=	MnzlV2FPT0WU
Mewo	M{faV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTl7LkW2NFMh\|ryP	MnLPV2FPT0WU
LU-65	NYjJWFlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTFyMT6wPFEh\|ryP	NGHxd\|hUSU6JRWK=
Saos-2	NULT[nh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmm4TWM2OD1zMEGuOFM4KM7:TR?=	NIGwdoxUSU6JRWK=
TE-11	NXmycGhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWP3[np5UUN3ME2xNFEvPzJ2IN88US=>	NH3UOFdUSU6JRWK=
SK-MES-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\MTWM2OD1zMEGuO\|YzKM7:TR?=	NUfEWYpxW0GQR1XS
KE-37	NGjIXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4flZ2lEPTB;MUCyMlk2KM7:TR?=	NUPDfolUW0GQR1XS
MKN45	NGfEXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHhXmRKSzVyPUGwN{42QDRizszN	M{LHNHNCVkeHUh?=
UM-UC-3	M2rjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13hU2lEPTB;MUCzMlg1OiEQvF2=	MXvTRW5ITVJ?
SNU-C2B	MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LnTWlEPTB;MUC1MlAzOyEQvF2=	M33pXXNCVkeHUh?=
RPMI-8226	NG\CUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTFyNj62O\|gh\|ryP	NWLoVVdnW0GQR1XS
PANC-08-13	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDwWIRIUUN3ME2xNFYvQDVizszN	Mnm0V2FPT0WU
NCI-H23	NXL2S5pKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTrTWM2OD1zMEiuN\|U4KM7:TR?=	MYTTRW5ITVJ?
HOP-92	M1vGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fZbmlEPTB;MUC4MlQ4PSEQvF2=	MkLKV2FPT0WU
FTC-133	MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrGZ3lKSzVyPUGwPE41QDhizszN	MVnTRW5ITVJ?
D-263MG	Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUezfWlNUUN3ME2xNFgvQTZzIN88US=>	NWDENoZIW0GQR1XS
DU-145	M3PkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPZTG9KSzVyPUGwPU46PDVizszN	Mlr3V2FPT0WU
A253	M1nHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTFzMD60O\|kh\|ryP	NFLXPVFUSU6JRWK=
HCT-15	M2PwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TpdmlEPTB;MUGwMlY3OSEQvF2=	M3XXNnNCVkeHUh?=
WSU-NHL	NYCyTXRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fCSWlEPTB;MUGyMlAyKM7:TR?=	MXLTRW5ITVJ?
U031	NHrlTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XrOGlEPTB;MUGyMlA3PSEQvF2=	NVnUSo42W0GQR1XS
MDA-MB-157	MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTFzMj60PUDPxE1?	NFT1d25USU6JRWK=
NEC8	NXPCO3FiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXpTWM2OD1zMUKuOlI1KM7:TR?=	NXv6cJNNW0GQR1XS
SIG-M5	Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjZNGJkUUN3ME2xNVMvOTJ3IN88US=>	NWXWTnVZW0GQR1XS
786-0	NFzu[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrnXZhCUUN3ME2xNVMvPDV\|IN88US=>	MlHQV2FPT0WU
DMS-273	NGHVR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjmPZVKSzVyPUGxOU43OTdizszN	NXjTXopqW0GQR1XS
Calu-6	NIjQTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTFzNj63PVgh\|ryP	Mn\xV2FPT0WU
HCC1599	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTFzNz6xOVYh\|ryP	M{nZbXNCVkeHUh?=
OVCAR-8	NHntS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\u[ZVKSzVyPUGxO{43PjhizszN	MnexV2FPT0WU
ATN-1	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfYOXJKSzVyPUGxO{45OjhizszN	NWXWOVZtW0GQR1XS
RKO	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIO4WGJKSzVyPUGxO{45QThizszN	MljZV2FPT0WU
SKG-IIIa	MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTFzOD6xNVYh\|ryP	NH3NS5JUSU6JRWK=
SUP-T1	NFTue2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzoOVBiUUN3ME2xNVgvQTV4IN88US=>	NXGw[2VJW0GQR1XS
KNS-81-FD	M{L4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXNTW1KSzVyPUGxPU41OTdizszN	MW\TRW5ITVJ?
OVCAR-3	NFPjNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjpTWM2OD1zMUmuPVE2KM7:TR?=	M1rVVHNCVkeHUh?=
NCI-N87	Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTF{MT6wOFQh\|ryP	Mln5V2FPT0WU
HuP-T4	NFjjWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTye\|NKSzVyPUGyNU42PSEQvF2=	NUfufZZtW0GQR1XS
KYSE-140	M1TaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzpTWM2OD1zMkKuNVQyKM7:TR?=	NVnOTplZW0GQR1XS
HAL-01	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTF{Mj60PVkh\|ryP	NWTEd\|NTW0GQR1XS
HT-29	M1\IPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHqxeotKSzVyPUGyNk44PzhizszN	NYLpWHNKW0GQR1XS
OPM-2	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvafGlmUUN3ME2xNlMvOTd4IN88US=>	NIrJeYVUSU6JRWK=
SW1463	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfFbpYzUUN3ME2xNlQvODd5IN88US=>	NYnLUYV3W0GQR1XS
NCI-H2087	NHXa[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHQNplLUUN3ME2xNlQvOjh\|IN88US=>	MnfaV2FPT0WU
UMC-11	M3\4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDEc5VKSzVyPUGyOk4xOzhizszN	MlL5V2FPT0WU
EB-3	NEXVcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTF{Nz6wNVMh\|ryP	MW\TRW5ITVJ?
HEC-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoD5TWM2OD1zMkmuNVk5KM7:TR?=	NGDKV4JUSU6JRWK=
LU-99A	M{DDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjWOG9TUUN3ME2xNlkvQTNzIN88US=>	MnTVV2FPT0WU
VMRC-RCZ	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\oV5R6UUN3ME2xN\|AvOzd3IN88US=>	MkPaV2FPT0WU
MFH-ino	M1zUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TGcWlEPTB;MUOxMlEyPCEQvF2=	M{\xWHNCVkeHUh?=
HT-1080	M3Lud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHRTWM2OD1zM{KuNlA1KM7:TR?=	NFnxO3FUSU6JRWK=
CTB-1	NV:2THo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HiVWlEPTB;MUOyMlg6PyEQvF2=	NHjWVpJUSU6JRWK=
Capan-2	NXKxTHQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHvTWM2OD1zM{OuPVc2KM7:TR?=	MWXTRW5ITVJ?
BB30-HNC	M3TiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\LR3VoUUN3ME2xN\|QvOTF4IN88US=>	MnzPV2FPT0WU
CP50-MEL-B	M4\u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3W5fGlEPTB;MUO0MlIh\|ryP	NEjzXWRUSU6JRWK=
JEG-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zGVWlEPTB;MUO0MlM2QSEQvF2=	Ml\oV2FPT0WU
NCI-H1437	NVi3fW1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PabWlEPTB;MUO0MlU6KM7:TR?=	NXL3U20zW0GQR1XS
NOS-1	NWrlUXdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;YPWlEPTB;MUO0Mlc3PSEQvF2=	NIX6cm5USU6JRWK=
G-402	M1TtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTF\|NT6yPVUh\|ryP	NX\5UY02W0GQR1XS
OAW-42	Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTF\|Nz64OVYh\|ryP	MnnrV2FPT0WU
Ca-Ski	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzrTWM2OD1zM{iuPFMyKM7:TR?=	MnHqV2FPT0WU
BHT-101	M2Lidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX6w[nVxUUN3ME2xOFAvOjB6IN88US=>	NILkNo5USU6JRWK=
OVCAR-4	NFrybndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHWdFhKSzVyPUG0NE44PDlizszN	NGf2OnhUSU6JRWK=
Detroit562	NVWxPHE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4r0e2lEPTB;MUSxMlQ3PiEQvF2=	M3z2R3NCVkeHUh?=
OCI-AML2	M3HBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjBV2hrUUN3ME2xOFEvPTB5IN88US=>	M4LZTnNCVkeHUh?=
OE33	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XyPGlEPTB;MUSxMlc6QCEQvF2=	M4PyPHNCVkeHUh?=
YKG-1	NYntcW5jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTF2Mj64PFkh\|ryP	NXjBXYpNW0GQR1XS
CCF-STTG1	NGjCUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTF2Mz6zN\|Qh\|ryP	NEDMUJlUSU6JRWK=
NCI-H810	NXvZPJZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LmdGlEPTB;MUSzMlY5PyEQvF2=	M3qxdnNCVkeHUh?=
SCC-25	M4jWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\kTWM2OD1zNESuNFA2KM7:TR?=	NXixR2FRW0GQR1XS
HTC-C3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2L5ZWlEPTB;MUS1MlA4PSEQvF2=	M37URXNCVkeHUh?=
G-401	M4T5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jzbWlEPTB;MUS1Mlg{PSEQvF2=	NVnZSFBxW0GQR1XS
OMC-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3P4SWlEPTB;MUS1Mlk3PyEQvF2=	MYnTRW5ITVJ?
LK-2	M1HlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrjV2M6UUN3ME2xOFcvOTR\|IN88US=>	MmizV2FPT0WU
SW13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTF2Nz6yOVMh\|ryP	MmPaV2FPT0WU
BB49-HNC	NX;1PHBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M131SGlEPTB;MUS3MlQxPCEQvF2=	Mo\uV2FPT0WU
DMS-114	NUH5VHk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDNXmFKSzVyPUG0O{41PDFizszN	NYTFNo86W0GQR1XS
GCIY	M3jQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;ETWlEPTB;MUS3Mlc6PyEQvF2=	NVPjdGZKW0GQR1XS
GAMG	NISyNXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmn2TWM2OD1zNEiuNlQ4KM7:TR?=	MlPWV2FPT0WU
KYSE-520	MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\m[2lEPTB;MUS4MlU1KM7:TR?=	MoXKV2FPT0WU
LB647-SCLC	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzMNFZNUUN3ME2xOFgvPTZ{IN88US=>	NGPDZ\|JUSU6JRWK=
639-V	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDwdlZZUUN3ME2xOFgvPzB3IN88US=>	NFHPbpRUSU6JRWK=
TE-9	NVLiflVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M170ZmlEPTB;MUS5MlQ1OyEQvF2=	NV;VTY9[W0GQR1XS
Caov-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fVd2lEPTB;MUS5MlcyPCEQvF2=	MVXTRW5ITVJ?
L-540	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnNc4tIUUN3ME2xOFkvPzVizszN	NEnmdohUSU6JRWK=
NCI-H748	NFHEdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPwfJpKSzVyPUG1NE4zODlizszN	MnzrV2FPT0WU
GDM-1	MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTF3MT6xN\|Uh\|ryP	M1nSZnNCVkeHUh?=
GAK	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjPb4RKUUN3ME2xOVEvOzd2IN88US=>	MnHJV2FPT0WU
AsPC-1	NWjuTFdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV[5TpFPUUN3ME2xOVIvPzZ2IN88US=>	Mlr2V2FPT0WU
MDA-MB-361	M1nlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LRUmlEPTB;MUWzMlE3PCEQvF2=	M2PuWHNCVkeHUh?=
TT	M3OwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTF3Mz60PUDPxE1?	MnvqV2FPT0WU
Calu-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn71TWM2OD1zNUSuNFA{KM7:TR?=	MojnV2FPT0WU
RERF-LC-MS	M1HhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPQTnJMUUN3ME2xOVQvPzd{IN88US=>	NUDjc\|V7W0GQR1XS
DK-MG	NEj5elZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoGwTWM2OD1zNUWuNVg{KM7:TR?=	M{HKcnNCVkeHUh?=
CAL-120	NIjMO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPQZ5NxUUN3ME2xOVUvQDJzIN88US=>	MX;TRW5ITVJ?
HCC1419	NX30R3djT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTxRZZKSzVyPUG1Ok4xPzdizszN	NWjxNoNoW0GQR1XS
DG-75	MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGS4R4JKSzVyPUG1Ok43QTRizszN	M1nL[3NCVkeHUh?=
HCC38	NYHKSZJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml34TWM2OD1zNUeuN\|Y6KM7:TR?=	NUHKXJZ[W0GQR1XS
HCC70	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGP2fXhKSzVyPUG1PU4zPDJizszN	NH[2S3BUSU6JRWK=
ES4	MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIS5[5dKSzVyPUG1PU4{QTZizszN	MmLRV2FPT0WU
NCI-H2052	NET1fGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\XeYlKSzVyPUG1PU42QDNizszN	MYTTRW5ITVJ?
EFO-27	NXzFbZhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTF4MD61PFQh\|ryP	MWHTRW5ITVJ?
CAL-62	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPObo9zUUN3ME2xOlIvPjF\|IN88US=>	NV\uSJQ3W0GQR1XS
CHP-212	NXPKNY1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH65[IlKSzVyPUG2N{43OjZizszN	Mn7DV2FPT0WU
AU565	MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjmOphKSzVyPUG2N{43PCEQvF2=	NWrzTJU1W0GQR1XS
Ca9-22	NGXKW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTF4ND6zNlEh\|ryP	NXnDdFVrW0GQR1XS
EFO-21	NXnIXplET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXT2UXpVUUN3ME2xOlUvPDVizszN	MYrTRW5ITVJ?
KINGS-1	M{LKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTF4Nz6zOVQh\|ryP	NFu5XJBUSU6JRWK=
JVM-2	M4HRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrNTWM2OD1zNkeuOFUyKM7:TR?=	M1i2WnNCVkeHUh?=
OVCAR-5	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zEWWlEPTB;MU[4MlMxQSEQvF2=	MlPNV2FPT0WU
Calu-3	NEG0[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGf3U4lKSzVyPUG2PE4{OTFizszN	MW\TRW5ITVJ?
CP66-MEL	M33DVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfXUpRKSzVyPUG2PE41OTVizszN	MYjTRW5ITVJ?
KYSE-150	M1fNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\NTWM2OD1zNkmuOlM3KM7:TR?=	NHTzcGNUSU6JRWK=
Daoy	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInQOoFKSzVyPUG2PU45QTFizszN	M33qdXNCVkeHUh?=
HUTU-80	NHLTRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nyfmlEPTB;MUexMlA{OiEQvF2=	M2\zfnNCVkeHUh?=
SW620	Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTF5MT61N\|Uh\|ryP	MXfTRW5ITVJ?
HuO-3N1	M1XSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXSTWM2OD1zN{KuNlc{KM7:TR?=	MXrTRW5ITVJ?
HH	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7mTWM2OD1zN{OuPFQ5KM7:TR?=	M3;BbnNCVkeHUh?=
ME-180	NY\WdXJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;rTWM2OD1zN{SuNFE3KM7:TR?=	MVTTRW5ITVJ?
SW756	M1LENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTF5ND64OlMh\|ryP	NH7kTYdUSU6JRWK=
LNCaP-Clone-FGC	NVHWdm44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjITWM2OD1zN{WuPFYyKM7:TR?=	MoXqV2FPT0WU
YT	M3nlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zUZ2lEPTB;MUe2MlM6QSEQvF2=	M3zoT3NCVkeHUh?=
EW-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfCTWM2OD1zN{[uOVU2KM7:TR?=	NH;JdWlUSU6JRWK=
COLO-741	NGPrOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPHWo5KSzVyPUG3O{42PjFizszN	M2X1fHNCVkeHUh?=
SK-NEP-1	NGLFO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUKxT3ByUUN3ME2xO\|cvQDB4IN88US=>	MoLMV2FPT0WU
NB10	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4KxO2lEPTB;MUe3Mlg1PiEQvF2=	MkTqV2FPT0WU
SF126	NVfDRot6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPyTWM2OD1zN{muOFMzKM7:TR?=	NEHze3dUSU6JRWK=
NCI-H522	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTF6MT6wOVkh\|ryP	MXjTRW5ITVJ?
PSN1	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGm4TIdKSzVyPUG4NU43PiEQvF2=	NGPCWGtUSU6JRWK=
GI-ME-N	NHPnVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Lr[GlEPTB;MUixMlY4OiEQvF2=	MULTRW5ITVJ?
SBC-5	M3nicmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTF6MT65N\|Qh\|ryP	MnfmV2FPT0WU
ONS-76	M17McGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\GTWM2OD1zOEKuN\|g4KM7:TR?=	MX3TRW5ITVJ?
LOUCY	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHONW9KSzVyPUG4Nk43QDhizszN	NVvTbpFlW0GQR1XS
SN12C	NV:weWRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPRTm1KSzVyPUG4Nk45OjlizszN	M1exSXNCVkeHUh?=
A427	M{fPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;VTWM2OD1zOESuOlMyKM7:TR?=	Mn;KV2FPT0WU
DOK	M3Hicmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPITWM2OD1zOESuOlQ{KM7:TR?=	M3\PfHNCVkeHUh?=
MDA-MB-415	NIPBcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYS0Z4s6UUN3ME2xPFQvPjVzIN88US=>	MWrTRW5ITVJ?
MRK-nu-1	MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vtNGlEPTB;MUi0Mlk4OiEQvF2=	MlK5V2FPT0WU
LB2241-RCC	NWDtZm9lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLEbHBKSzVyPUG4OU4yPDVizszN	NHnhXHVUSU6JRWK=
NCI-H1563	NU\KfYZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\sWVJSUUN3ME2xPFUvOjB7IN88US=>	NEj1U2RUSU6JRWK=
MDA-MB-453	NYW5U2xkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDtdphKSzVyPUG4Ok46PDFizszN	M1vPcXNCVkeHUh?=
MONO-MAC-6	NXzpNGUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTF6Nz6zPVIh\|ryP	MYPTRW5ITVJ?
CAPAN-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmX6TWM2OD1zOEeuOFU{KM7:TR?=	MonoV2FPT0WU
SK-LU-1	M{nETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFGxWGVKSzVyPUG4PE41OjhizszN	M1;pbXNCVkeHUh?=
NCI-H1299	MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTF6OD63NVkh\|ryP	Mn3FV2FPT0WU
KG-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rQZWlEPTB;MUi5Mlc6QCEQvF2=	Mm\VV2FPT0WU
ETK-1	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XUWGlEPTB;MUmwMlE5OSEQvF2=	MkfGV2FPT0WU
NCI-H838	M2DhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDIUnk{UUN3ME2xPVAvOzRizszN	MYPTRW5ITVJ?
HCE-4	NFLxV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDSRYk6UUN3ME2xPVAvQTl{IN88US=>	NEOyNnhUSU6JRWK=
A2780	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LycWlEPTB;MUmyMlg6OSEQvF2=	NHXyUGhUSU6JRWK=
COLO-668	NHTmPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYT2OlNHUUN3ME2xPVMvOTV5IN88US=>	M1TPeXNCVkeHUh?=
HGC-27	MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVv5TmtQUUN3ME2xPVUvPTN6IN88US=>	MoHmV2FPT0WU
SW1088	NYKxZZoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlOwTWM2OD1zOUWuOlc4KM7:TR?=	NYTlNmwxW0GQR1XS
KOSC-2	M4H5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;ZcYpIUUN3ME2xPVUvQDF6IN88US=>	M3iyW3NCVkeHUh?=
TE-1	M{fhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTF7Nj6yOkDPxE1?	MlzYV2FPT0WU
SW780	MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTMNWVQUUN3ME2xPVYvPzN2IN88US=>	MnnjV2FPT0WU
22RV1	NIDlemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTF7Nz60NlQh\|ryP	M2rS[HNCVkeHUh?=
IA-LM	MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTnTWM2OD1zOUeuPFIzKM7:TR?=	NFr2N3FUSU6JRWK=
TE-5	M1nMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXuco8xUUN3ME2xPVgvODN\|IN88US=>	MlLJV2FPT0WU
JVM-3	NYHZc5h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnYcWVIUUN3ME2xPVgvPDF7IN88US=>	M1XXenNCVkeHUh?=
HT55	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU[zUoN1UUN3ME2xPVkvOTl{IN88US=>	MXrTRW5ITVJ?
QIMR-WIL	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVT3ZoUxUUN3ME2yNFAvOTF4IN88US=>	NVP2PHJuW0GQR1XS
SJRH30	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfsPGdUUUN3ME2yNFAvPTF3IN88US=>	NFP2WFRUSU6JRWK=
COLO-679	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LMbWlEPTB;MkCwMlg2QSEQvF2=	NF3kRoFUSU6JRWK=
MDA-MB-231	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnz4TWM2OD1{MECuPVAzKM7:TR?=	M13uZnNCVkeHUh?=
MFM-223	Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJyMT61PFch\|ryP	NH;mZo1USU6JRWK=
MFE-280	Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnDVYhKSzVyPUKwNU46PjFizszN	M2DKUnNCVkeHUh?=
LAMA-84	M{HVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV21W3BYUUN3ME2yNFIvODd\|IN88US=>	M4DhbXNCVkeHUh?=
LS-1034	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTJyMj61OVMh\|ryP	M2X5dHNCVkeHUh?=
NCI-H345	M2ixfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJyMz6wNlch\|ryP	MnfQV2FPT0WU
KYSE-70	Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJyMz64O\|kh\|ryP	NUfYN3oyW0GQR1XS
EGI-1	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTLTWM2OD1{MESuPFM{KM7:TR?=	NXXVSHg5W0GQR1XS
RPMI-2650	NYTmZ\|Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUj4NJNzUUN3ME2yNFUvPDZ5IN88US=>	MXnTRW5ITVJ?
NCI-H1651	NFjGcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\Z[lJKSzVyPUKwOk44OyEQvF2=	MWHTRW5ITVJ?
HPAF-II	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzrTWM2OD1{MEmuOlcyKM7:TR?=	MX3TRW5ITVJ?
NUGC-3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTJyOT62O\|gh\|ryP	M1To[XNCVkeHUh?=
DJM-1	NW\OflJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnxfJd5UUN3ME2yNFkvQDl5IN88US=>	MVrTRW5ITVJ?
MHH-PREB-1	M{T3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn30TWM2OD1{MUCuN\|gyKM7:TR?=	M3r0fXNCVkeHUh?=
EW-18	NXjlZpdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jEPWlEPTB;MkGwMlc3OyEQvF2=	MVHTRW5ITVJ?
BT-20	MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3W3UWlEPTB;MkGwMlk5PiEQvF2=	MYnTRW5ITVJ?
A431	NWXnOZdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1u4TGlEPTB;MkGxMlI6QSEQvF2=	M4XyU3NCVkeHUh?=
TCCSUP	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX[3eXpqUUN3ME2yNVEvPTN\|IN88US=>	NXPQWmFxW0GQR1XS
HO-1-N-1	NWe4[Gs5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\6bXdsUUN3ME2yNVIvQDl2IN88US=>	Mm\hV2FPT0WU
NCI-H69	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrX[pZKSzVyPUKxOE4yQDVizszN	NFLubHhUSU6JRWK=
ES7	NX7N[2loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTJzND64O\|gh\|ryP	MoTYV2FPT0WU
C3A	M1LWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3:1S2lEPTB;MkG1MlU4PSEQvF2=	M1XtNXNCVkeHUh?=
UACC-257	M1\0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PyXWlEPTB;MkG3MlQ{KM7:TR?=	MVvTRW5ITVJ?
DMS-153	NVe4TWo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJzNz64N\|Yh\|ryP	MWDTRW5ITVJ?
LB771-HNC	M4\U[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnu1TWM2OD1{MUeuPFk{KM7:TR?=	NYDRUpZvW0GQR1XS
HOS	NX3YSpdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHvVWpZUUN3ME2yNVgvQSEQvF2=	NH7TXJlUSU6JRWK=
THP-1	MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPqTGpwUUN3ME2yNVkvPjB4IN88US=>	M4DiOXNCVkeHUh?=
SCC-4	M4LKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJ{MD6zOVMh\|ryP	MUDTRW5ITVJ?
SCC-3	M3vvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTJ{MD61O\|ch\|ryP	NFG2enpUSU6JRWK=
BC-1	MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHJdo5KSzVyPUKyNE44QTlizszN	NFnR[nlUSU6JRWK=
NCI-H1618	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTJ{MT6wNVgh\|ryP	NIroR3pUSU6JRWK=
CaR-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DCb2lEPTB;MkKxMlI2OSEQvF2=	NFXKcJNUSU6JRWK=
NCI-H1355	NEPWfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7jTWM2OD1{MkGuN\|c4KM7:TR?=	M{K4[3NCVkeHUh?=
NCI-H1993	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkO3TWM2OD1{MkKuNlM6KM7:TR?=	MVPTRW5ITVJ?
NCI-H1623	NWXNU4hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTJ{Mj6zPFkh\|ryP	NYXmOotYW0GQR1XS
AGS	MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DJWGlEPTB;MkKyMlUzOyEQvF2=	NULoXlNsW0GQR1XS
SAS	M2fNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTJ{Mz63PVYh\|ryP	MUDTRW5ITVJ?
HCC1937	NULXNFBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLlTWM2OD1{MkSuN\|g6KM7:TR?=	MVfTRW5ITVJ?
NCI-H209	M3mw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETZWohKSzVyPUKyOk42OyEQvF2=	NVPZWW1PW0GQR1XS
NCI-H322M	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDXWFlKSzVyPUKyPE4xOTlizszN	MnrvV2FPT0WU
CHL-1	M2qzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTJ{OD6xN{DPxE1?	MmDOV2FPT0WU
NCI-H630	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrQU\|dwUUN3ME2yN\|IvQDl5IN88US=>	NWi0fFd3W0GQR1XS
5637	NGHpeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LIUmlEPTB;MkOzMlAxOyEQvF2=	NVvhUoFsW0GQR1XS
MSTO-211H	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvtRXF[UUN3ME2yN\|MvOjd4IN88US=>	M3;4PHNCVkeHUh?=
YAPC	NF;aT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\6TWM2OD1{M{SuNlU{KM7:TR?=	MmDHV2FPT0WU
SW1783	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfCTWM2OD1{M{SuOFEh\|ryP	MV\TRW5ITVJ?
GB-1	M{PRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXMb25KSzVyPUKzOU4yPzdizszN	NVO0PGJpW0GQR1XS
NCI-H520	NF\0eYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTJ\|NT63OFEh\|ryP	Moi0V2FPT0WU
NOMO-1	M{POcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnpTWZzUUN3ME2yN\|YvODJizszN	Mon3V2FPT0WU
NCCIT	MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHOd4JKSzVyPUKzOk45PzNizszN	NWHjRppYW0GQR1XS
SW954	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknMTWM2OD1{M{euPFY5KM7:TR?=	NHrYOohUSU6JRWK=
MOLT-4	NYHvV21ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTJ2MT6yNFkh\|ryP	MmXQV2FPT0WU
EB2	NEX5VXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVqzWG5xUUN3ME2yOFEvQTB5IN88US=>	NH65bVZUSU6JRWK=
IPC-298	NHr2SWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHBPFVKSzVyPUK0Nk4xPzJizszN	M2KzXXNCVkeHUh?=
GP5d	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJ2Mj62NVYh\|ryP	NWjVSlVtW0GQR1XS
HN	NGXneJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLUTWM2OD1{NEKuPVkyKM7:TR?=	M3HqUHNCVkeHUh?=
BFTC-909	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTJ2Mz6xNVgh\|ryP	NFTrTYpUSU6JRWK=
ES5	NEG2RZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7re5BKSzVyPUK0OU4xOzhizszN	MV\TRW5ITVJ?
SK-HEP-1	MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDFNVd4UUN3ME2yOFYvODR\|IN88US=>	MVXTRW5ITVJ?
T47D	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTJ2Nz6wNVMh\|ryP	NYfIS3FnW0GQR1XS
KYSE-510	MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV60PI91UUN3ME2yOFcvPTF5IN88US=>	MnnBV2FPT0WU
LC-1F	M3[3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGGwWZFKSzVyPUK0PE4yPTZizszN	MmXsV2FPT0WU
NCI-H1693	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPaTWM2OD1{NEmuOFk2KM7:TR?=	MkCzV2FPT0WU
COR-L23	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\zTWM2OD1{NUCuOFEzKM7:TR?=	M2XpUnNCVkeHUh?=
NCI-H2228	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\VV\|RRUUN3ME2yOVAvQDZ2IN88US=>	M2H4eXNCVkeHUh?=
NCI-H460	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHSTWM2OD1{NUGuOFE4KM7:TR?=	M4XHWHNCVkeHUh?=
TGBC1TKB	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;2PVI5UUN3ME2yOVIvQDd3IN88US=>	NEHqXZpUSU6JRWK=
NCI-H1304	NFjGbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;TbGlEPTB;MkWzMlE2PiEQvF2=	MWnTRW5ITVJ?
CAL-27	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLxTWM2OD1{NUOuOFg2KM7:TR?=	NXn2bWplW0GQR1XS
NCI-H187	NUezOZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP0TWM2OD1{NU[uO\|Yh\|ryP	MYPTRW5ITVJ?
HSC-2	M4Lhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Cyb2lEPTB;MkW4MlU5PCEQvF2=	Mmm2V2FPT0WU
CAL-39	M4f2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLhTWM2OD1{NkCuNlczKM7:TR?=	NVPLRYNwW0GQR1XS
HuH-7	M1zQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLzTWM2OD1{NkCuPVk3KM7:TR?=	NXTUe5RLW0GQR1XS
MMAC-SF	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nLdWlEPTB;Mk[xMlE6OiEQvF2=	NInTWllUSU6JRWK=
VA-ES-BJ	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPkbVNWUUN3ME2yOlEvQTF6IN88US=>	MVjTRW5ITVJ?
A673	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJ4Nz6wNlUh\|ryP	NHWxdWJUSU6JRWK=
LU-165	M2f3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHk[JhXUUN3ME2yOlcvQTRzIN88US=>	MoTjV2FPT0WU
CAL-12T	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2KyZWlEPTB;Mk[4MlM3PiEQvF2=	M3zDWnNCVkeHUh?=
RD	NWjHfWVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTJ4OT6xNVkh\|ryP	NVzhfpFQW0GQR1XS
MDA-MB-468	M{WzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTJ4OT6zN\|Mh\|ryP	NE[xUYFUSU6JRWK=
LN-405	NFSxToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlyxTWM2OD1{NkmuO\|A5KM7:TR?=	MYrTRW5ITVJ?
MHH-CALL-2	MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPnfHhxUUN3ME2yOlkvQTJizszN	MkK4V2FPT0WU
ES3	M1zvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnlT\|lGUUN3ME2yO\|AvOzV6IN88US=>	NHjCRYRUSU6JRWK=
SK-MEL-3	NInh[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{G3cmlEPTB;Mke1MlQ2PyEQvF2=	MorEV2FPT0WU
TE-10	NFnPOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XOd2lEPTB;Mke2MlQ{QSEQvF2=	NV3TWYxEW0GQR1XS
BEN	NUPh[lc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HocGlEPTB;Mke2MlQ3OSEQvF2=	M{nJOnNCVkeHUh?=
NB69	M3XBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DrfmlEPTB;Mke3MlQxPSEQvF2=	MULTRW5ITVJ?
CAMA-1	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvm[VVKSzVyPUK3PE4zPzlizszN	MkPmV2FPT0WU
NCI-H1792	NY\Pb3pKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHiNHFKSzVyPUK3PU4yQDdizszN	MoSyV2FPT0WU
UACC-893	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrzOmNqUUN3ME2yPFAvPTRizszN	M2LsVHNCVkeHUh?=
TGW	M4jnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJ6Mz6wOVgh\|ryP	MnvSV2FPT0WU
SH-4	NGr6ZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vNUmlEPTB;MkizMlEzOyEQvF2=	Mn;0V2FPT0WU
NCI-H2009	M4DwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4WzSGlEPTB;MkizMlk2OyEQvF2=	M2G5[3NCVkeHUh?=
T84	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2K2[GlEPTB;Mki0MlY3PSEQvF2=	M1rsS3NCVkeHUh?=
EW-7	MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorJTWM2OD1{OEWuNlMzKM7:TR?=	M2GwTnNCVkeHUh?=
NCI-H1882	M{L5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrjTWM2OD1{OE[uNFM2KM7:TR?=	M4LQbXNCVkeHUh?=
GMS-10	M1LHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJ6Nz6xPFMh\|ryP	M{nTe3NCVkeHUh?=
HC-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTJ7MD62NFIh\|ryP	M3PiSnNCVkeHUh?=
ABC-1	NHrlOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTJ7MT6wOlkh\|ryP	NFfoUWFUSU6JRWK=
HuP-T3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmGxTWM2OD1{OUKuNVQ3KM7:TR?=	NE\GXpdUSU6JRWK=
HT-1197	NILBfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHL6WVhKSzVyPUK5Nk45PzlizszN	MnHaV2FPT0WU
SHP-77	M2Htd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fyVGlEPTB;Mkm1MlU6PyEQvF2=	MmC3V2FPT0WU
NCI-H524	MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rZWWlEPTB;Mkm1Mlc3QSEQvF2=	NUOzVHV2W0GQR1XS
SW626	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEn5RWlKSzVyPUK5Ok4yOTVizszN	MlO2V2FPT0WU
NCI-H2347	M3e5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XSb2lEPTB;Mkm2MlQzPSEQvF2=	MoG4V2FPT0WU
U251	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;GWoxKSzVyPUK5PE41OzhizszN	NHzFdpBUSU6JRWK=
RL95-2	MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlW5TWM2OD1\|MECuNlQ4KM7:TR?=	NVLKRmhUW0GQR1XS
C2BBe1	NGPLWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvXSG9KSzVyPUOwNE43QTFizszN	NGT2S3hUSU6JRWK=
HLE	NEjpZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXG4WWpuUUN3ME2zNFEvQDF6IN88US=>	NWjFPXRVW0GQR1XS
COLO-680N	NIfjTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NET1XldKSzVyPUOwNk45QTNizszN	MWLTRW5ITVJ?
PLC-PRF-5	M{\PXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Wxe2lEPTB;M{C0MlkxPyEQvF2=	MWPTRW5ITVJ?
SCC-15	NEnGd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjjU2lUUUN3ME2zNFYvODF5IN88US=>	MkPKV2FPT0WU
ECC12	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDrdHlKSzVyPUOxNE4zPTRizszN	Ml\YV2FPT0WU
A388	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;rXVFKSzVyPUOxNk4xOjJizszN	MWDTRW5ITVJ?
ES1	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVyxZXhXUUN3ME2zNVIvOTh7IN88US=>	NGrqN3VUSU6JRWK=
J-RT3-T3-5	NFq2[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzjUXpKUUN3ME2zNVMvPTJzIN88US=>	MULTRW5ITVJ?
SNU-475	MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\sUWVbUUN3ME2zNVQvODlzIN88US=>	MVLTRW5ITVJ?
647-V	M4LuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHjXphKSzVyPUOxOE43PzNizszN	MoLGV2FPT0WU
IMR-5	NV7mfGN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rRRmlEPTB;M{G1MlM5KM7:TR?=	MlPrV2FPT0WU
EW-24	M1K4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7KTWM2OD1\|MkCuNFch\|ryP	MnrXV2FPT0WU
CAL-51	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkD6TWM2OD1\|MkGuOFA{KM7:TR?=	NWnqUYU1W0GQR1XS
HD-MY-Z	MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnCXlJKSzVyPUOyNU41ODlizszN	MWLTRW5ITVJ?
EW-13	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XNVWlEPTB;M{KyMlQzPCEQvF2=	NWfOd5k{W0GQR1XS
SK-N-FI	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTN{Mj60OVIh\|ryP	M{fSUXNCVkeHUh?=
BHY	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTN{Mz6xO\|Uh\|ryP	MXjTRW5ITVJ?
OCUB-M	M1jjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDZe49WUUN3ME2zNlMvPDN2IN88US=>	NWK3cJVvW0GQR1XS
HCC1954	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnQeoVKSzVyPUOyN{42QDJizszN	MnfBV2FPT0WU
SK-MEL-24	NYnPW2x2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;SdZo5UUN3ME2zNlQvOTFzIN88US=>	NHnMVHdUSU6JRWK=
NTERA-S-cl-D1	Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHiSoxWUUN3ME2zNlYvPDh7IN88US=>	MXPTRW5ITVJ?
SK-MEL-30	MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTN{Nj63N\|gh\|ryP	MY\TRW5ITVJ?
LS-123	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzUVpFvUUN3ME2zNlgvOTZ2IN88US=>	M1\kXHNCVkeHUh?=
SF268	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYj2cXVYUUN3ME2zN\|AvOjZ3IN88US=>	MU\TRW5ITVJ?
BT-474	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTN\|Mj60NVgh\|ryP	NGjqN5VUSU6JRWK=
NCI-H1522	NVPwb3J6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYriWZBDUUN3ME2zN\|QvOzN7IN88US=>	MYPTRW5ITVJ?
LC-2-ad	M2i1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3KwS2lEPTB;M{O2MlU6OSEQvF2=	NWLa[2pUW0GQR1XS
LAN-6	NEX4NolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTN\|Nj65O\|ch\|ryP	MkfYV2FPT0WU
ARH-77	NWfaOHNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTN\|Nz6zNkDPxE1?	MnnhV2FPT0WU
HuO9	M32ySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DzPGlEPTB;M{O3MlQ4KM7:TR?=	NV;hcHQ1W0GQR1XS
MLMA	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWGwSmxvUUN3ME2zN\|gvOTV3IN88US=>	Mnz5V2FPT0WU
Raji	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnoW3dGUUN3ME2zN\|gvOzhizszN	NX7OPHpWW0GQR1XS
GT3TKB	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;WT\|ZKSzVyPUOzPE41OTJizszN	MlX2V2FPT0WU
NCI-H441	NHjENFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTsTWM2OD1\|NEGuOFE5KM7:TR?=	MXrTRW5ITVJ?
NCI-H2030	NEX2XIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LGS2lEPTB;M{SxMlYxQSEQvF2=	M33LV3NCVkeHUh?=
VM-CUB-1	M{nCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEWye2JKSzVyPUO0Nk43OzZizszN	MkjJV2FPT0WU
KP-4	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmWxTWM2OD1\|NEOuO\|M{KM7:TR?=	M4\0OXNCVkeHUh?=
PF-382	NUjyeGVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDOTWM2OD1\|NESuOFIzKM7:TR?=	NXrrUINmW0GQR1XS
NB13	MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPTTWM2OD1\|NEWuOVgh\|ryP	NWe1TlJZW0GQR1XS
D-502MG	M1\tXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPEWYFRUUN3ME2zOFUvQDF{IN88US=>	MWnTRW5ITVJ?
CAL-54	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zwfWlEPTB;M{S1Mlg4QSEQvF2=	MoTxV2FPT0WU
DOHH-2	M1\HeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTN2Nj62OUDPxE1?	NH7Ed2hUSU6JRWK=
SK-PN-DW	NWPkbpllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPZSo5KSzVyPUO0O{41OjZizszN	NV;3R5U4W0GQR1XS
NCI-H720	NIDkUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTyTWM2OD1\|NEmuPFQ3KM7:TR?=	Mmf1V2FPT0WU
SW1990	NFLyU\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTN3MT6yPEDPxE1?	NEn0TYlUSU6JRWK=
NCI-H2196	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLz[nRKSzVyPUO1Nk43OjRizszN	NEfDTlhUSU6JRWK=
P30-OHK	MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTN3Mz6wOlMh\|ryP	M3HyVHNCVkeHUh?=
NCI-H358	M2PN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13hWWlEPTB;M{W1MlM2PiEQvF2=	MUnTRW5ITVJ?
CW-2	NH3rSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XhWmlEPTB;M{W2MlUzQSEQvF2=	M{HjbXNCVkeHUh?=
COLO-678	M{\JV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTN3Nz64OlMh\|ryP	Mk\xV2FPT0WU
NCI-H2126	NWHiU3h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4j0dmlEPTB;M{W4MlUzOSEQvF2=	MmG1V2FPT0WU
DMS-53	NFe3cYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NED1[oNKSzVyPUO1PE44OTFizszN	NH\1fJhUSU6JRWK=
NCI-H1838	M2e5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2r2ZWlEPTB;M{W5Mlk5PyEQvF2=	MWXTRW5ITVJ?
SJSA-1	NFTQTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTN4MD65N\|kh\|ryP	MlK2V2FPT0WU
ChaGo-K-1	M1;Se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTN4Mz65NlQh\|ryP	NF;QNpRUSU6JRWK=
IST-SL2	Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jsUGlEPTB;M{eyMlkzPiEQvF2=	MnjUV2FPT0WU
U-266	M4DuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2X6NmlEPTB;M{ezMlE{OiEQvF2=	MXrTRW5ITVJ?
P31-FUJ	MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTET4c5UUN3ME2zO\|YvQTZ2IN88US=>	NIW1dFBUSU6JRWK=
HCC2157	NHG0VHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrtTVBKSzVyPUO3PE4yPjFizszN	Mn7wV2FPT0WU
COR-L88	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTiTWM2OD1\|OEOuOlc4KM7:TR?=	NE\vTlVUSU6JRWK=
NCI-H596	MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHTZpNKSzVyPUO4OU4{PCEQvF2=	NYrySoY3W0GQR1XS
GOTO	NHLtbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHQTWM2OD1\|OUCuOlQyKM7:TR?=	NVq1eIxvW0GQR1XS
NCI-H719	NXjRRW5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTsdmxPUUN3ME2zPVEvQDl\|IN88US=>	NU\FbWRqW0GQR1XS
MN-60	NGXpWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTN7Mz65OFgh\|ryP	MVXTRW5ITVJ?
IST-SL1	NIrxXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDjTWM2OD1\|OUSuOFA3KM7:TR?=	Mn3wV2FPT0WU
TE-6	M3;p[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPMeFlKSzVyPUO5O{4zPTRizszN	NUjjemNPW0GQR1XS
SW962	NGLGcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTjR3J1UUN3ME2zPVgvPjlizszN	MnO1V2FPT0WU
FADU	M1vTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLQcGdKSzVyPUSwN{4xQDNizszN	MUfTRW5ITVJ?
ECC4	M1rx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHq4VpNKSzVyPUSwPE41PThizszN	NV3IUVZIW0GQR1XS
MES-SA	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfSdJRKSzVyPUSwPU46QCEQvF2=	M3f6S3NCVkeHUh?=
NCI-H716	NHPxb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTRzMD6wO\|Uh\|ryP	M2frPXNCVkeHUh?=
GR-ST	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnTTWM2OD12MUCuOFk4KM7:TR?=	M3nacXNCVkeHUh?=
KY821	NVrzTIE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvpfXpKSzVyPUSxOE4xQDZizszN	M{TVW3NCVkeHUh?=
NCI-H2141	NI[5OJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fsNWlEPTB;NEK0MlM5QCEQvF2=	MWfTRW5ITVJ?
MDA-MB-134-VI	NXXTXoJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTR\|MT6wN\|Mh\|ryP	M4[wUXNCVkeHUh?=
RH-1	NX[5dWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTR\|NT6wPUDPxE1?	MWrTRW5ITVJ?
AM-38	NI[xXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXLTWM2OD12M{iuOVQh\|ryP	MlL3V2FPT0WU
BL-70	NE[0SWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWCzNJBIUUN3ME20N\|kvPDJ7IN88US=>	NGK4[JlUSU6JRWK=
COLO-684	M1XoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXlUGtKSzVyPUS0PE45QDhizszN	NI\o[IlUSU6JRWK=
DMS-79	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHnTWM2OD12NEmuOlgh\|ryP	M3TaWnNCVkeHUh?=
EW-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjoe5RuUUN3ME20OVIvQDh6IN88US=>	M4XrT3NCVkeHUh?=
MS-1	NES1TGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3znNWlEPTB;NEW0MlM5PSEQvF2=	NIf4b\|hUSU6JRWK=
A4-Fuk	M3;WcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzITWM2OD12NUSuOVA4KM7:TR?=	NUHNeXEyW0GQR1XS
TALL-1	NI\xZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DkPGlEPTB;NEW1MlI6PyEQvF2=	MX3TRW5ITVJ?
SCLC-21H	NWTHV3luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnqTWM2OD12NUWuOlk6KM7:TR?=	NFjOcGhUSU6JRWK=
KMS-12-PE	NUX2O4NHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3wT4VKSzVyPUS1Ok45OjJizszN	MnTMV2FPT0WU
TE-441-T	M3vRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXsbYRKSzVyPUS1O{4yQDZizszN	NInpbVlUSU6JRWK=
A3-KAW	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXhSmdKSzVyPUS2NE45PDFizszN	NFv0dYJUSU6JRWK=
NCI-H1092	MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rRXmlEPTB;NE[zMlk1OyEQvF2=	M3TVN3NCVkeHUh?=
COR-L279	NH7iS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjCUXFKSzVyPUS2OE45PDdizszN	M1rpNHNCVkeHUh?=
NCI-SNU-5	NWLuXmpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7JSVZjUUN3ME20O\|IvOjhizszN	NEDHPItUSU6JRWK=
JAR	M4fPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDLfoI{UUN3ME20O\|QvPzh6IN88US=>	MXPTRW5ITVJ?
NCI-H446	NUL0c\|hUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2CyfmlEPTB;NEe3MlA5KM7:TR?=	MVzTRW5ITVJ?
HDLM-2	NGm1SGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvuTWM2OD12OECuPFY6KM7:TR?=	NYDNNJNiW0GQR1XS
D-283MED	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13MfWlEPTB;NEi4MlkzPCEQvF2=	M{LkZ3NCVkeHUh?=
NCI-H1395	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\DSW93UUN3ME20PFkvODB2IN88US=>	NX7jfZA4W0GQR1XS
RPMI-6666	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\BTWM2OD12OUGuN\|k5KM7:TR?=	NVPj[4RWW0GQR1XS
CPC-N	Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoG0TWM2OD13MEKuNFY{KM7:TR?=	NHeycFZUSU6JRWK=
EC-GI-10	NHnEd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTVyMj6xOlkh\|ryP	MWTTRW5ITVJ?
CA46	NF;1ZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHQTWM2OD13MESuOFA4KM7:TR?=	NXXLdFZXW0GQR1XS
EHEB	M1Pzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnQTWM2OD13MEeuNlA5KM7:TR?=	NGPTWlFUSU6JRWK=
RPMI-8402	MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTVzMD6wNlEh\|ryP	Ml7JV2FPT0WU
DU-4475	MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnIcpFKSzVyPUWxNU4yODFizszN	NVmxV4RRW0GQR1XS
P12-ICHIKAWA	MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrxTWM2OD13MUGuOFE3KM7:TR?=	NWHYR5NCW0GQR1XS
NCI-H1694	Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXm4VGtJUUN3ME21NVIvPDN7IN88US=>	NHz0d2RUSU6JRWK=
NCI-H2171	MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTMTWM2OD13MUKuO\|A2KM7:TR?=	MnrPV2FPT0WU
Mo-T	M2[zVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXINWVKSzVyPUWxOU4yOTZizszN	M1\EWnNCVkeHUh?=
HL-60	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPVZYlyUUN3ME21NlIvQTJ2IN88US=>	MnWxV2FPT0WU
NCI-H1436	NFPsXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPHTWM2OD13MkOuNFY1KM7:TR?=	MVPTRW5ITVJ?
NCI-H510A	M4HMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTV{ND62PVYh\|ryP	NUHsWXZMW0GQR1XS
NCI-H2081	NFjqPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7jdpZKSzVyPUWyOU42OTNizszN	NF7MVlJUSU6JRWK=
NB5	MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NID5U5dKSzVyPUWyOk41OyEQvF2=	MYHTRW5ITVJ?
NCI-H2227	NELiTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;GblZkUUN3ME21N\|AvOjV2IN88US=>	M4\nWHNCVkeHUh?=
HSC-4	Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3K[Wc1UUN3ME21N\|kvOjl\|IN88US=>	M1Tje3NCVkeHUh?=
RL	NXjKT29[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfjUZNKSzVyPUW0Nk41PDJizszN	MYLTRW5ITVJ?
EVSA-T	NEPibXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPOdVU3UUN3ME21OFMvPjh2IN88US=>	NFzQe\|JUSU6JRWK=
NCI-H889	M1X6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXmWFBoUUN3ME21OFcvOjNizszN	NXmzXZBYW0GQR1XS
COLO-320-HSR	M4DvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;hN2lEPTB;NUWxMlM2KM7:TR?=	MXrTRW5ITVJ?
EW-11	NUD6[JN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;uTWM2OD13NUKuN\|k6KM7:TR?=	MXnTRW5ITVJ?
UACC-812	NGSxSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3foXWlEPTB;NUW5MlM6OSEQvF2=	M1zwTnNCVkeHUh?=
CAL-148	NYj1WoxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTV4NT6wPFkh\|ryP	M3T0N3NCVkeHUh?=
K052	M3TESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XFfGlEPTB;NUe5MlIyOyEQvF2=	MkTPV2FPT0WU
L-428	NEDqNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;6WIpuUUN3ME22NFAvPjdzIN88US=>	M2rLd3NCVkeHUh?=
LP-1	MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTZyMz61PFch\|ryP	MXXTRW5ITVJ?
ML-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;pUmlEPTB;NkC2MlU4QSEQvF2=	M16yfnNCVkeHUh?=
KARPAS-45	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTjTWM2OD14MUiuNlIyKM7:TR?=	NXHJO3o1W0GQR1XS
HT	MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvPO25KSzVyPU[yNk44QDVizszN	NYTDSIFPW0GQR1XS
NCI-H226	NXzMRphkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLWNIlLUUN3ME22NlgvOzV\|IN88US=>	MnH3V2FPT0WU
L-363	Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\qd3hKSzVyPU[0PE4xPjRizszN	MYjTRW5ITVJ?
IM-9	NUjHV3JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHv5T5JKSzVyPU[1NU42PDFizszN	NIXCTZdUSU6JRWK=
TUR	NE\rOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTZ5MT6zNlIh\|ryP	NFrYZlFUSU6JRWK=
NCI-SNU-16	NVHQd4ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXafFVIUUN3ME22PFAvPDZ{IN88US=>	NI[w[ndUSU6JRWK=
NCI-SNU-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHtXIFKSzVyPU[5NE4yPzJizszN	NHrZTYlUSU6JRWK=
U-87-MG	M4rvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;FSZBqUUN3ME22PVQvPTh3IN88US=>	MkPUV2FPT0WU
KM-H2	NHT0R\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVK4UHV3UUN3ME22PVkvODV7IN88US=>	NGjJXXhUSU6JRWK=
DEL	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmL2TWM2OD15MECuPFM5KM7:TR?=	M4OzfnNCVkeHUh?=
KARPAS-422	M{TQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrD[\|JKSzVyPUe4PU4{OTVizszN	M17TbXNCVkeHUh?=
BC-3	NFLw[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrqcW1lUUN3ME24NFUvOjB\|IN88US=>	NF3Le4ZUSU6JRWK=
NCI-H1155	NGr0cGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TxeWlEPTB;OEG4MlA2QSEQvF2=	NHrreo5USU6JRWK=
NCI-H1581	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTlyMD6yN\|Eh\|ryP	NX7m[YlNW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo

Oral administration of CHIR-99021 at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. Oral administration of CHIR-99021 at 16 or 48 mg/kg 1 hour before oral glucose challenges in ZDF rats significantly improves glucose tolerance with 14% and 33% reduction in plasma glucose at 16 mg/kg and 48 mg/kg, respectively, and the higher dose of CHIR-99021 also reduces hyperglycemia before the oral glucose challenge. ^[1] Administration of CHIR-99021 significantly augments hematopoietic repopulation in recipient mice transplanted with mouse or human hematopoietic stem cells (HSCs), suggesting that GSK-3 is a specific modulator of HSC activity. ^[4]

Protocol

Kinase Assay: ^[1]	+ Expand Cell-free kinase assays: Polypropylene 96-well plates are filled with 300 μL/well buffer (50 mM tris HCl, 10 mM MgCl₂, 1 mM EGTA, 1 mM dithiothreitol, 25 mM β-glycerophosphate, 1 mM NaF, 0.01% BSA, pH 7.5) containing 27 nM GSK-3α or 29 nM GSK-3β, and 0.5 μM biotin-CREB peptide substrate. Various concentrations of CHIR-99021 are added in 3.5 μL of DMSO, followed by 50 μL of ATP stock to yield a final concentration of 1 μM ATP in all cell-free assays. After incubation, triplicate 100-μL aliquots are transferred to Combiplate eight plates containing 100 μL/well 50 μM ATP and 20 mM EDTA. After 1 hour, the wells are rinsed five times with PBS, filled with 200 μL of scintillation fluid, sealed, left 30 minutes, and counted in a scintillation counter. All steps are performed at room temperature.
Cell Research: ^[3]	+ Expand Cell lines: INS-1E Concentrations: Dissolved in DMSO, final concentrations ~ 20 μM Incubation Time: 1, or 4 days Method: Cells are maintained for 24 hours in starvation medium (culture medium with only 5 mM glucose, 1% fetal calf serum). Then cells are exposed to various concentrations of CHIR-99021 for 1, or 4 days. Cell number is measured by staining of cellular DNA with CyQuant dye, which becomes fluorescent when bound to DNA. Fluorescence is measured after 30 minutes of incubation using the FLUOstar Optima reader. Cell replication is determined by BrdUrd incorporation. BrdUrd labeling solution is added to the medium for the last 4 hours before the cells are fixed using FixDenat solution and incubated with monoclonal anti-BrdUrd-POD antibodies. After substrate solution is added to each well, the light emission is measured in a microplate luminometer using the Analyst HT detection system. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Female db/db mice or male ZDF rats with type 2 diabetes Formulation: Formulated as solutions in 20 mM citrate-buffered 15% Captisol or as fine suspensions in 0.5% carboxymethylcellulose. Dosages: ~48 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	93 mg/mL (185.33 mM)
	Ethanol	2 mg/mL (3.98 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	24mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Molecular Weight	501.8
Formula	C₂₂H₁₈Cl₂N_8.HCl
CAS No.	1797989-42-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I recently purchased CHIR 99021 to inject mice intraperitoneally. The data sheet says using 10% captisol for in vivo use. Is it for IP injection? Or do you have other solutions to suggest to use for in vivo IP injection of CHIR 99021?
Answer:
The formulation of 15% Captisol is for oral gavage, and S2924 CHIR-99021 (CT99021) HCl in it is a suspension. S2924 CHIR-99021 (CT99021) HCl can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 24mg/ml as a clear solution for IP injection.
Question 2:
How about the half-life of this compound? If it is necessary for daily treatment when the compound is used in long-term experiment?
Answer:
Please change the culture medium each day to add the new comound in it if the duration is more than 72h.
Question 3:
What is the difference between S2924 and S1263? Which one is better for differentiation?
Answer:
S1263 is the free base format of Chir-99021, while S2924 is the HCl salt format. They have the same biological activity but are slightly different in solubility.

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Selective GSK-3 Inhibitor

TWS119 : GSK-3β-selective, IC50 of 30 nM.
Most Potent GSK-3 Inhibitor

CHIR-98014 : GSK-3α, IC50=0.65 nM; GSK-3β, IC50=0.58 nM.
GSK-3 Inhibitor in Clinical Trial

Tideglusib : Phase II for Alzheimer's disease.
Newest GSK-3 Inhibitor

AZD1080 : Orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with K_i of 6.9 nM and 31 nM, respectively.

Related GSK-3 Products4

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
LY2090314 ^New

LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of kinases.
TDZD-8 ^New

TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.
TWS119

TWS119 is a GSK-3β inhibitor with IC50 of 30 nM in a cell-free assay; capable of inducing neuronal differentiation and may be useful to stem cell biology.
SB216763

SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β.
Tideglusib

Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.
CHIR-98014

CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.
BIO

BIO is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor.

Features:The first pharmacological agent shown to maintain self-renewal in human and mouse embryonic stem cells.
AR-A014418

AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and K_i of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.
IM-12

IM-12 is a selective GSK-3β inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling.

Choose Your Country or Region

By Signaling Pathways

By product type

CHIR-99021 (CT99021) HCl

Cited by 73 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Related GSK-3 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

CHIR-99021 (CT99021) HCl

Cited by 73 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Related GSK-3 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)